

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The use of Patient-Reported Outcome Measures (PROMs) in clinical diabetes consultations: study protocol for the DiaPROM randomized controlled trial.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024008
Article Type:	Protocol
Date Submitted by the Author:	24-May-2018
Complete List of Authors:	Haugstvedt, Anne; Hogskulen pa Vestlandet, Department of Health and Caring Sciences Hernar, Ingvild; Hogskulen pa Vestlandet, Department of Health and Caring Sciences; Univeristy of Bergen, Department of Global Public Health and Primary Care Strandberg, Ragnhild ; Hogskulen pa Vestlandet, Department of Health and Caring Sciences Richards, David; University of Exeter, Medical School Nilsen, Roy; Hogskulen pa Vestlandet, Department of Health and Caring Sciences Tell, Grethe; University of Bergen, Department of Global Public Health and Primary Care Graue, Marit; Hogskulen pa Vestlandet, Department of Health and Caring Sciences
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3
4 The use of Patient-Reported Outcome Measures (PROMs) in
5
6
7 clinical diabetes consultations: study protocol for the
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The use of Patient-Reported Outcome Measures (PROMs) in clinical diabetes consultations: study protocol for the DiaPROM randomized controlled trial

Anne Haugstvedt,¹ Ingvild Hernar,^{1,2,3} Ragnhild B Strandberg,¹ David Richards,⁴
Roy M Nilsen,¹ Grethe S Tell,² Marit Graue¹

¹Department of Health and Caring Sciences, Western Norway University of Applied Sciences,
Bergen, Norway

²Department of Global Public Health and Primary Care, University of Bergen, Bergen,
Norway

³Department of Medicine, Haukeland University Hospital, Bergen, Norway

⁴Institute for Health Research, University of Exeter Medical School, Exeter, UK

Correspondence to: Anne Haugstvedt, Department of Health and Caring Sciences, Western
Norway University of Applied Sciences, Post Box 7030, N-5020 Bergen, Norway. Tel: +47
55 58 78 88; Mobile +47 47 82 92 20. E-mail: ahau@hvl.no

Word count in Abstract: 269

Word count in main text: 3997

ABSTRACT

Introduction Although diabetes distress is found to be associated with decreased glycaemic control among adults with type 1 diabetes, the psychological and emotional impact of living with the disease is often not recognized and often underreported in diabetes care. Therefore, regular assessment of diabetes distress is recommended. Assessment of diabetes distress using Patient-Reported Outcome Measures (PROMs) in clinical practice has the potential to enhance care for people with diabetes by identifying problems and improving patient-clinician communication. In this study, we aim to develop, test and evaluate the effectiveness of an empowerment-based intervention using PROMs regarding diabetes distress as dialogue support in clinical diabetes consultations among adults with type 1 diabetes.

Methods and analysis As part of the implementation of PROMs in the Norwegian Diabetes Register for Adults, we will utilize PROMs data to improve the quality of clinical diabetes consultations. The study is a randomized controlled trial among adults with type 1 diabetes. We used the Medical Research Council's framework as a guide when developing the study and this protocol describes three of the four phases in this framework: (1) the development phase, (2) the feasibility and piloting phase, and (3) the evaluation phase. Both quantitative and qualitative approaches will be used in the various study phases. In the evaluation phase, the effect of the study intervention will be analysed with linear regression and mixed models.

Ethics and dissemination Ethical approval has been obtained from the Western Norway Regional Committee for Medical and Health Research Ethics for the feasibility study (2016/2200/REC west) and the pilot and randomized controlled trial evaluation study (2017/1506/REC west). Trial registration number ClinicalTrials.gov ID: NCT03471104

Keywords Type 1 diabetes, Diabetes distress, Patient-Reported Outcome Measures (PROMs), Complex intervention

Strengths and limitations of the study

- This is a comprehensive study with the potential to provide new knowledge about the use of Patient-Reported Outcome Measures (PROMs) as dialogue support in clinical diabetes consultations to reduce diabetes distress among patients with type 1 diabetes.
- The use of the Medical Research Council's framework as a guide for the development and evaluation of this randomized controlled trial is a strength because appropriate methodological and practical choices can be made in all phases of the study.
- A key challenge includes possible contamination of the control group although the completed PROMs will not be available in the medical records of the participants in the control group.

INTRODUCTION

The management of type 1 diabetes (T1D) is complex and people living with the condition need to make numerous daily choices related to their medical treatment.[1, 2] They need to monitor their blood glucose and administer insulin several times each day. The burden of living with T1D remains a challenge despite new insulin types and advances in insulin delivery and glucose monitoring technologies.[3] Many Norwegian adults with T1D do not achieve the recommended treatment goals for glycaemic control.[4, 5] This poor goal attainment might be due to inappropriate choice of insulin regimen for the individual, but research has also shown psychological and emotional aspects are important barriers to satisfactory diabetes self-management.[6]

The psychological and emotional impact of living with diabetes is often unrecognized and/or underreported in diabetes care.[7, 8] Diabetes distress, which reflects the emotional response to the burden, worries, anxieties, frustrations and stressors associated with managing diabetes in everyday life,[9, 10] is found to be associated with decreased glycaemic control.[11, 12] Therefore, the International Diabetes Federation recommends regular assessment of diabetes distress.[13] Such assessment is considered feasible and beneficial to promote the recognition of psychological and emotional issues that affect diabetes self-management.[9, 14]

Patient-Reported Outcome Measures (PROMs) involves asking people to complete questionnaires concerning the impact of their condition and its treatment on their health.[15] The integration of PROMs in clinical practice has the potential to improve care for people with diabetes and other chronic diseases by screening for and identifying problems, monitoring progress over time, improving patient-clinician communication and enabling

1
2
3 patients to become more involved in managing their own health.[16] The present study is part
4
5 of the implementation of PROMs in the Norwegian Diabetes Register for Adults (NDR-A).
6
7

8 **Aim**

9

10
11 The overarching aim of the Diabetes Patient-Reported Outcome Measures
12 (DiaPROM) trial is to develop, test and evaluate the effectiveness of a structured
13
14 empowerment-based intervention using PROMs regarding diabetes distress as dialogue
15
16 support in clinical diabetes consultations among adults with T1D. The primary hypothesis is
17
18 that the intervention will reduce diabetes distress. A secondary hypothesis is that the
19
20 intervention will improve overall well-being, perceived competence for diabetes management,
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS AND ANALYSIS

Study design and study overview

The study is designed as a multidisciplinary randomized controlled intervention trial (RCT) and will consist of several interacting components and a number of behaviours required by those receiving and delivering the intervention. Therefore, we used the Medical Research Council's framework (MRC framework) as a guide when developing the study.[17, 18] The framework describes four important phases in the development, evaluation and implementation of a new intervention initiative: (1) the development phase, (2) the feasibility and piloting phase, (3) the evaluation phase and (4) the implementation phase (figure 1). In this protocol, we will present the study gradually according to the first three phases. The first two phases are the preparatory phases and phase 3 comprises the full-powered RCT. An overview of the phases is presented in Table 1.

Table 1. Overview of the study phases in the DiaPROM trial

Phase	Aims	Methods	Participants
Phase 1: Development	To perform a literature review and meet with health service users to identify relevant PROMs, develop a method for answering PROMs and develop an intervention following PROM scores of concern	Systematic literature searches related to the use of PROMs in interventions, and consultations with several health service users, both individual and in groups	3 persons with type 1 diabetes (individually), and 3 persons with diabetes (in a group)
Phase 2: Feasibility and piloting			
2a: Feasibility study	To feasibility test the technical and practical procedures for collecting PROMs on a touch screen computer, and evaluate the participants' perceived understanding, relevance and number of questions	Qualitative approach (field notes), and quantitative approach (analyse questionnaire data on perceived understanding, relevance and number of questions)	At least 60 patients with type 1 diabetes ≥ 40 years
2b: Pilot study	To test all the components of the upcoming full-powered RCT	RCT design with outcome measures at baseline and after 1 year. Audiotaping of nurse consultations and qualitative interviews with participants and health care personnel	80 (40 + 40) patients with type 1 diabetes (18–40 years), 6–8 nurse consultations, 15–20 participants and 8–10 physicians and nurses
Phase 3: Evaluation	To evaluate the effectiveness of a structured empowerment-based intervention with the use of PROMs as dialogue support in clinical diabetes consultations	RCT design with outcome measures at baseline, after 1 year and after 2 years. A qualitative approach will be considered based on experiences from the pilot study	A power analysis indicated a need for 77 participants (included 20% dropouts) in each group, but the pilot study will inform the final sample size calculation

We used the SPIRIT checklist (<http://www.spirit-statement.org/wp-content/uploads/2013/01/SPIRIT-Checklist-download-8Jan13.pdf>) to make sure that all important and recommended items are addressed in the study protocol.

Phase 1: development of the study

The initial development of the DiaPROM trial took place during 2016 and 2017. The essential tasks in the development phase were to determine (1) which PROMs to include, (2) how patients should complete the PROMs, and (3) which intervention should follow PROMs scores of special concern.

Literature review

We performed systematic literature searches to identify published articles on the use of PROMs in clinical diabetes intervention studies. Regarding the use of PROMs in clinical practice, we identified a multi-centre study across eight countries that had tested the feasibility and impact of a procedure for implementing PROMs in routine diabetes care.[14,19] This computer-assisted “Monitoring of Individual Needs in Diabetes” procedure aimed to improve recognition and management of the psychological needs of patients with diabetes in routine care. Regular assessment of psychological needs was implemented as part of the annual review in diabetes clinics. The assessment included diabetes distress measured by the Problem Areas in Diabetes (PAID) scale. Several other studies have reported PAID as an appropriate instrument for use in clinical diabetes consultations. This instrument may contribute to improved communication by making the dialogue between health care providers and patients more therapeutic and goal oriented.[20-25] The PAID scale has been translated into several languages, including Norwegian.[26]

Patient and public involvement

A crucial question when considering which PROMs to include was what adult people with T1D perceived as the most important and relevant aspects to emphasize in diabetes follow-up. Thus, we consulted several groups of health service users. The health service users indicated that the 20 statements in PAID were relevant to a life with diabetes. In addition, they experienced the burden of completing PAID and the study’s evaluation measures as acceptable for the participants. To include the voice of the health service users throughout the study, two people with diabetes are included in the project group. They will contribute in all phases of the study. Furthermore, we will invite additional people with diabetes to share their views on the various phases of the study. Involving health service users at different levels

(from consultation to contribution) is important to provide insight into patients' perspectives and useful in terms of shaping the research processes.[27]

Intervention PROMs

Based on the literature review and input from the health service users, we chose the PAID scale as the tool for dialogue support in the study intervention. The scale was developed to gain insight into the breadth of emotional responses to living with diabetes and consists of 20 statements regarding diabetes distress (e.g. "feeling constantly concerned about food and eating", "worrying about low blood sugar reactions").[28-30] The scores are on a 5-point Likert scale from 0 (not a problem) to 4 (serious problem). An item score of 3 (somewhat serious problem) or 4 (serious problem) indicates moderate to serious diabetes distress related to the specific item. Scale scores are transformed to a 0-100 scale, with higher scores indicating greater distress.

Completing PROMs

The literature describes various methods for administration of PROMs such as paper-based self-administration at home or in the clinic, interviews by telephone or personal meetings, computer-assisted self-administration in the clinic or mail- or web-based administration from patients' homes.[16] In our study, we decided on computer-assisted administration on a touch screen computer in the outpatient clinic. Using this method has advantages, such as efficient and simultaneous data entry and minor privacy challenges.

The study intervention

Based on the literature review and input from the health service users, we developed the study intervention that we aim to evaluate in phase 3. The starting point for the intervention is when participants complete the PAID scale and physicians download the scores into the participants' medical record as part of the annual consultation (figure 2).

1
2
3 Further, physicians will review and discuss the PAID scores briefly with participants.
4
5 Participants with one or more single PAID item(s) score of 3 or 4 (somewhat serious or
6
7 serious problem), or PAID total score ≥ 30 , will be referred to additional diabetes nurse
8
9 consultations. Participants with lower scores will receive regular follow-up according to usual
10
11 clinical protocols.
12
13

14
15 The nurse follow-up for those with PAID scores of concern will consist of at least two
16
17 consultations. The first will take place within 4 weeks after the annual consultation and
18
19 inclusion in the trial, and the second within 3 months after the first. After the second nurse
20
21 consultation, the nurse and the participant will agree on any further follow-up until the next
22
23 annual consultation with the physician. The diabetes nurses' review of PAID scores in
24
25 conversation with participants will follow a communication manual based on key elements
26
27 from empowerment theory and self-determination theory, such as empathetic communication
28
29 and autonomy support.[31-33] The communication skills highlighted in the manual involve
30
31 "active listening", "asking open questions", "responding", "summing up" and "agreeing on
32
33 goals and actions to take". For further work with the participants problem areas, goals and
34
35 actions to take will be written on a separate form. Finally, 12 months after inclusion, the
36
37 participants will complete the PAID again before the annual consultation with the physician.
38
39

40 41 *Evaluation measures* 42

43
44 The measurements used to measure the effect of the evaluation study (phase 3) were
45
46 also chosen on the basis of the literature review and considerations in the development phase.
47
48 Diabetes distress, measured by the Diabetes Distress Scale (DDS), has been chosen as the
49
50 primary outcome in the study. The DDS contains 17 items and 4 subscales: emotional burden
51
52 (5 items), physician-related distress (4 items), regimen distress (5 items) and diabetes-related
53
54 interpersonal distress (3 items).[34] The scores are on a 6-point Likert scale from 1 (not a
55
56
57
58
59
60

1
2
3 problem) to 6 (serious problem) with a mean total or subscale score from 1 to 6.[35] As
4
5 secondary outcomes, the World Health Organization's 5-item well-being index (WHO-5)[36-
6
7 38] and the Perceived Competence for Diabetes Scale (PCDS)[39-41] are included for
8
9 evaluation of overall well-being and perceived diabetes competence, respectively.
10
11

12
13 The participants will complete both the PAID and the evaluation PROMs before the
14
15 annual consultation, and some standard questions about satisfaction with follow-up in health
16
17 care will be completed after the same consultation.
18
19

20 21 **Phase 2a: feasibility study**

22
23 A feasibility study started in 2017 with the aims of (1) examining the technical and
24
25 practical feasibility of collecting PROMs on a touch screen computer in the outpatient clinic,
26
27 and (2) evaluating the participants' perceived understanding, the number and relevance of
28
29 items, and the acceptability of completing PROMs annually. The participants in the feasibility
30
31 study were adults with T1D aged ≥ 40 years from Haukeland University Hospital in western
32
33 Norway.
34
35

36 37 *Data collection and outcomes*

38
39 The data collection has been completed. Regarding the first aim, field observations
40
41 provided data on the technical and practical procedures related to the completion of PROMs
42
43 on the touch screen computer. Informal conversations with participants and health care
44
45 personnel about their experiences also took place. Regarding perceived understanding,
46
47 relevance and number of items, and acceptability of completing PROMs annually, we
48
49 included a paper-based questionnaire with questions adapted for this study.
50
51
52
53
54
55
56
57
58
59
60

Data analysis

The data analysis is ongoing and will be completed in 2018. The field notes from the observations and informal conversations will be grouped by themes explaining the main content of the notes. The perceived understanding, the number and relevance of items and acceptability have been analysed descriptively. As additional analyses, we have estimated the proportion of participants meeting the inclusion criteria, the proportion of eligible patients showing up at the clinic and the proportion completing the PROMs. These estimates will give important information on recruitment of participants for the upcoming pilot and evaluation study.

Preliminary results

Almost 20% of 137 invited patients did not show up at the clinic (change of appointments, sick, no reason given). Further, most of the invited participants did not go directly to the computer on arrival at the clinic as instructed on the information sheet. Thus, we need to develop clearer information and procedures for the pilot study to avoid loss of potential participants among those invited. Sixty-nine individuals participated in the study and 83% of them reported that, to a high or a very high degree, they would be positive about an annual completion of PROMs. Further analyses of the results from the feasibility study are ongoing, and we plan to publish these in a separate article.

Phase 2b: pilot study

A pilot study will be conducted to test the feasibility of all the components of the forthcoming full-powered RCT; thus, the pilot will be designed as a randomized controlled trial in the same way as the evaluation study (phase 3). The aims of the pilot study are to:

1. evaluate the recruitment and the number of dropouts during the intervention;
2. evaluate the performance of the randomization procedure;

3. evaluate if the PAID scores qualifying for referral to nurse consultations seem suitable;
4. evaluate the variance in participants' outcome measurements and the estimated between-group differences and their 95% confidence intervals (CI);
5. evaluate if the intervention consultations are suitable and conducted in accordance with the given procedure; and
6. explore the patients' and health care personnel's experiences with the use of PAID as dialogue support in clinical diabetes consultations.

Participants

In accordance with recommendations for pilot RCTs of interventions,[42] we will include 80 participants: 40 in the intervention group and 40 in the control group. The participants should have T1D for at least 1 year and aged ≥ 18 to < 40 years. The same inclusion and exclusion criteria as described for the evaluation study will be applied. At inclusion, we will test the computer-based randomization procedure described for the evaluation study. The participants allocated to the intervention group will receive the described intervention with all its components. Thus, the pilot study will last for a year.

Data collection and outcomes

All participants (both intervention and control groups) will complete the study PROMs (before the annual consultation) and a paper-based questionnaire about their experience and satisfaction with the diabetes follow-up (after the consultation) at baseline and after 12 months (at the end of the intervention). Regarding data entry of these data, range checks for data values will be performed. We will document all types of contacts between the participants and the diabetes outpatient clinic for all participants throughout the study period. The outcome measures will be identical to the outcome measures described for the evaluation study.

To test if the extra consultations by diabetes nurses are carried out in accordance with the procedure described for the intervention, a random selection of consultations (6–8) will be audiotaped. For this audiotaping, we will obtain additional consent from the patients and from the nurses. Qualitative in-depth interviews with 15–20 participants and 8–10 health care personnel (physicians and nurses) will be conducted after the intervention regarding their experiences with the intervention and the use of PAID as dialogue support in clinical consultations.

Data analysis

In accordance with the aims of the pilot study, the recruitment of participants, the number of dropouts during the intervention, the performance of the randomization procedure, and the participants' PAID scores will be analysed descriptively. To evaluate the variance in the outcome measures and the estimated between-group differences, we will estimate the mean, SD and CI of the DDS and the other evaluation measurements before and after the intervention period for both the intervention and control groups. To evaluate whether the intervention consultations were suitable and conducted in accordance with the given procedures, we will transcribe the audiotaped consultations and analyse them using thematic analysis.[43] The interviews to evaluate the patients' and health care personnel's experiences with the use of PAID in the clinical consultations will also be transcribed and analysed with thematic analysis.

Phase 3: the evaluation study (the RCT)

The primary aim of the full-powered study is to evaluate the effectiveness of the structured empowerment-based intervention with the use of PROMs as dialogue support in clinical diabetes consultations in accordance with the overarching aim of the DiaPROM trial.

1
2
3 Our procedures may be modified on the basis of data collected from the feasibility and pilot
4
5 studies.
6

7 8 *Participants and eligibility criteria* 9

10
11 As in the pilot study, participants will be adults with T1D for at least 1 year aged from
12 ≥ 18 to < 40 years recruited from two university hospitals in western Norway. Pregnant
13 women, patients with severe somatic or psychiatric co-morbidities and people unable to read
14 and complete questionnaires on the computer because of language, reading, or cognitive
15 problems will be excluded. Eligible participants will receive information and consent forms
16 by regular mail before the annual diabetes consultation at the clinic. The information form
17 include information about volunteerism and the possibility to withdraw from the study at any
18 time point without consequences.
19
20
21
22
23
24
25
26
27

28 29 *Sample size calculations* 30

31
32 Preliminary power calculations have been performed based on a power of 80% and a
33 significance level of 5% to detect the minimal clinically important difference (MCID) in DDS
34 scores between the intervention group and the control group after the intervention. The MCID
35 is set to 0.4 for DDS scores from 1 to 6. A review of health-related quality of life instruments
36 by Normann *et al.*[44] found that the MCID estimates often appear to be half an SD. Previous
37 Norwegian data from Strandberg *et al.*[11] indicated a mean score (SD) of 2.0 (0.8) for the
38 DDS, yielding half SD of approximately 0.4. This is consistent with Fisher *et al.*[35] who
39 indicated 0.4 as a clinically meaningful difference in DDS, which was also half SD in that
40 study. The power calculations based on these data indicate that 64 participants in each group
41 will be sufficient to detect a treatment difference after the intervention. To account for
42 dropout (20%), we will include at least 77 participants in each group. However, we will
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 update the power calculations after the pilot study has been conducted to take post-
4
5 intervention between-group estimates (means and SDs) into account.
6
7

8 *Randomization procedure and allocation concealment*

9

10 We will use computer-generated block randomization at the patient level to ensure
11
12 equal numbers of participants in the intervention and control groups. Further, we will stratify
13
14 for gender to secure equal numbers of men and women in each group. When participants
15
16 complete the PROMs on the touch screen computer, they will receive an individual four-
17
18 character code. When the physician downloads the PROMs data using the code, a concealed
19
20 computerized allocation will take place. Information about which group the person is
21
22 allocated will appear on the computer screen and the physician will inform the participant
23
24 immediately. Thus, neither the participants nor the health care providers can be blinded.
25
26
27

28 *The intervention*

29

30
31 Participants allocated to the intervention group will receive the intervention described
32
33 in the development section (p. 8). The intervention will last for a year; from one annual
34
35 consultation to the next. For most patients the annual consultations normally constitute “care
36
37 as usual”. All participants will receive their usual care. The intervention will constitute an
38
39 additional care.
40
41
42

43 *The control group*

44

45
46 The control group will receive “care as usual” which does not include a structured
47
48 focus on psychological and emotional diabetes distress. All participants complete the PROMs
49
50 scores before an annual consultation. The randomization take place afterwards. However, for
51
52 the participants allocated to the control group, the scores will not be accessible in the
53
54 electronic patient records until the study is completed.
55
56
57
58
59
60

Data collection and outcomes

Participants will complete the primary and secondary outcome measures at baseline, at 12 months (after the intervention) and at 24 months follow-up. For subgroup analyses, we will perform a computerized retrieval of the following variables from the participants' electronic patient records: sex, age, ethnicity, body mass index, diabetes duration, HbA_{1c}, insulin regimen, insulin doses, severe hypoglycaemic episodes needing assistance in the past year, hospitalizations, co-morbidities and diabetes late complications.

Data analysis

To assess both short- and long-term effects of the intervention, we will collect one pre-intervention measure and two post-intervention (after 1 and 2 years) measures for both the intervention and control group. All analyses will be on an intention-to-treat basis, and we will compare intervention and control groups for each follow-up time using linear mixed effects models with DDS as the primary outcome measure. All models will define intervention, time and intervention-by-time interaction as fixed effects (all categorical), whereas a random intercept will be specified to account for correlated observations of the same individual (an exchangeable correlation structure assumed). To obtain *p* values or 95% CI for difference in DDS means between the comparison groups at different time points, we will perform a post-hoc test for pairwise comparison accounting for multiple testing. To test whether the predicted DDS means change differently over time, we will use the likelihood ratio test by comparing the log-likelihood between models with and without the intervention-by-time interaction. In linear mixed effects models, all available DDS measures for an individual will be used for estimation even though certain measures may be missing on follow-up for that individual. The model will produce unbiased estimates provided the data are missing at random. As this is a

1
2
3 block-randomized trial, we will assume that the comparison groups are similar in all aspects
4
5 except the treatment.
6

7 8 *Qualitative approach* 9

10
11 In addition to the quantitative evaluation of the study effect, we will explore the
12
13 patients' and health care personnel's experiences of the intervention's effectiveness and
14
15 appropriateness. However, data and analyses from the qualitative approaches in the pilot
16
17 study will be considered before deciding on the final strategy and procedures for the
18
19 qualitative approach in the evaluation study.
20
21

22 23 **ETHICS AND DISSEMINATION** 24 25

26
27 The Norwegian Regional Committee for Medical and Health Research Ethics has
28
29 approved the feasibility study (2016/2200/REK west) and the pilot and evaluation study
30
31 (2017/1506/REK west). Haukeland University Hospital, Bergen, Norway is the responsible
32
33 research institution (trial sponsor) where the study data will be stored on a secure research
34
35 server. In order to protect confidentiality, names of the potential and enrolled participants will
36
37 be stored separate from the other study data. Only the principle investigator and a few
38
39 members of the project group have access to the study data. If important protocol
40
41 modifications happen, this will be communicated to the ethic committee and
42
43 ClinicalTrials.gov. Further information and contact data can be obtained from
44
45 ClinicalTrials.gov, registration number NCT03471104.
46
47
48

49
50 Completing the PROMs may activate latent psychological or psychosocial problems
51
52 and negative feelings. To care for any participants in the control group reporting worryingly
53
54 high levels of distress, the research team will continuously review the reported distress levels
55
56
57
58
59
60

1
2
3 and discuss with the physicians the possible need for more intensive care or referral to
4 psychological or psychiatric follow-up for those reporting worryingly levels of distress.
5
6
7

8 We will present the findings of the study phases at national and international
9 conferences and submit manuscripts to peer-reviewed journals and popular science journals.
10 We will also publish the findings in popular science journals, public newspapers and journals
11 for relevant user groups.
12
13
14
15

16 **DISCUSSION**

17
18
19
20
21 In this multi-phase study, we have used relevant literature and input from health
22 service users in selecting PAID to focus on diabetes distress as a component of the
23 intervention. Schmitt *et al.*[25] emphasize the necessity of a justified choice of measurement
24 and recommend the use of the PAID when the clinical or scientific purpose is to assess a
25 variety of emotional concerns related to living with diabetes. Carlsen *et al.*[45] found that the
26 use of PAID could benefit patients but emphasized the need for follow-up studies to evaluate
27 whether the PAID should be implemented in routine diabetes care.
28
29
30
31
32
33
34
35

36
37
38 The choice of PAID as the intervention tool and the DDS as the primary evaluation
39 tool is in accordance with previous research. Both instruments have previously shown
40 satisfactory psychometric properties to map individual levels of diabetes distress, but it has
41 been claimed that the PAID has some advantages for use in clinical practice and the DDS
42 might have some advantages for use in clinical trials, because it also contributes to identifying
43 sub-domains of distress.[11, 25]
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations

The use of the MRC framework is a strength in the development of this study, because it includes several complex and interacting components that need to be considered and tested before conducting a full-scale randomized controlled trial.

We have included primarily disease-specific evaluation measures, but also one generic PROM (WHO-5). Disease-specific PROMs are used to capture information that is most pertinent to particular patient groups, but they might miss domains affecting the patient that are unrelated to their disease.[16, 46] Generic instruments may capture broad dimensions of health and allow for comparisons between populations but might not be sensitive to changes in disease-specific health domains over time or in relation to interventions.[15]

The fact that the control group in the study will also complete the PAID and the evaluation PROMs before the annual diabetes consultation, and that the same physicians meet participants from both the intervention and the control groups might lead to intervention contamination challenges. This might be a challenge although the scores will not be accessible in the electronic patient records of participants in the control group. The pilot study will provide important information about the extent of this challenge and will be considered before the sample size calculation for the evaluation study.

Acknowledgements

Thanks to the Norwegian Nurses Association, the Norwegian Diabetes Association and Western Norway University of Applied Sciences for funding the study. Thanks also to the Norwegian Diabetes Register for Adults and DIPS AS for fruitful collaboration. Further, we thank all the health care personnel and the health care service user representatives involved in the study. Thanks also to senior research fellow Peter Craig for giving us the permission to

1
2
3 reproduce the figure describing the study phases in the development and implementation of a
4
5 complex intervention.
6
7

8 **Contributors**

9
10
11 AH, IH, RBS, RMN, GST, DR and MG contributed to the design of the study. AH
12
13 drafted the manuscript for the study protocol. All authors contributed to editing the final
14
15 manuscript.
16
17

18 **Funding**

19
20
21
22
23 The study is funded by the Norwegian Nurse Association, Western Norway University
24
25 of Applied Sciences, the Norwegian Diabetes Association and the Norwegian Diabetes
26
27 Register for Adults. The first two funded a postdoctoral position and a PhD position,
28
29 respectively. The last two contributed with running funds.
30
31

32 **Competing interests**

33
34
35
36 None declared.
37
38

39 **Patient consent**

40
41
42
43
44 Obtained.
45
46

47 **REFERENCES**

- 48
49
50
51 1. American Association of Diabetes Educators (ADE). AADE7 Self-Care Behaviors.
52
53 *Diabetes Educ* 2008;34:445-9.
54
55
56
57
58
59

2. American Diabetes Association (ADA). Introduction: standards of medical care in diabetes. *Diabetes Care* 2018;41(Suppl 1):1-2. Available from: <<https://doi.org/10.2337/dc18-Sint01>> (Accessed Jan 22, 2018).
3. Jones A, Vallis M, Pouwer F. If it does not significantly change HbA 1c levels why should we waste time on it? A plea for the prioritization of psychological well-being in people with diabetes. *Diabet Med* 2015;32:155-63.
4. Cooper JG, Claudi T, Thordarson HB, *et al.* Treatment of type 1 diabetes in the specialist health service-data from the Norwegian Diabetes Register for Adults. *J Norwegian Med Assoc* 2013;133:2257.
5. Carlsen K, Haugstvedt A, Graue M. [PAID as screening and working tool in clinical consultations]. *Norwegian J Clin Nurs* 2015;10:228-37 [in Norwegian].
6. Pouwer F, Nefs G, Nouwen A. Adverse effects of depression on glyceemic control and health outcomes in people with diabetes: a review. *Endocrinol Metab Clin North Am* 2013;42:529-44.
7. Pouwer F, Beekman ATF, Lubach C, *et al.* Nurses' recognition and registration of depression, anxiety and diabetes-specific emotional problems in outpatients with diabetes mellitus. *Patient Educ Couns* 2006;60:235-40.
8. Peyrot M, Rubin RR, Lauritzen T, *et al.* Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. *Diabet Med* 2005;22:1379-85.
9. Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. *Diabet Med* 2014;31:764-72.

10. Snoek FJ, Bremmer MA, Hermanns N. Constructs of depression and distress in diabetes: time for an appraisal. *Lancet Diabetes Endocrinol* 2015;3:450-60.
11. Strandberg RB, Graue M, Wentzel-Larsen T, *et al.* Longitudinal relationship between diabetes-specific emotional distress and follow-up HbA_{1c} in adults with Type 1 diabetes mellitus. *Diabet Med* 2015;32:1304-10.
12. Fisher L, Hessler D, Polonsky W, *et al.* Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time. *J Diabetes Complications* 2016;30:1123-8.
13. International Diabetes Federation. *International Diabetes Federation Diabetes Atlas* [Online]. 8th ed. International Diabetes Federation; 2017. Available from: <http://www.diabetesatlas.org/resources/2017-atlas.html> (accessed Jan 15, 2018).
14. Snoek FJ, Kersch NY, Eldrup E, *et al.* Monitoring of Individual Needs in Diabetes (MIND)-2: follow-up data from the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) MIND study. *Diabetes Care* 2012;35:2128-32.
15. Greenhalgh J, Dalkin S, Gooding K, *et al.* Functionality and feedback: a realist synthesis of the collation, interpretation and utilisation of patient-reported outcome measures data to improve patient care. *Health Serv Deliv Res* 2017;5.2.
16. Snyder CF, Aaronson NK, Choucair AK, *et al.* Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. *Qual Life Res* 2012;21:1305-14.
17. Craig P, Dieppe P, Macintyre S, *et al.* Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;337:979-83.
18. Craig, P. Developing and evaluating complex interventions: reflections on the 2008 MRC guidance. *Int J Nurs Stud* 2013;50:585-92.

19. Snoek, FJ, Kersch NY, Eldrup E, *et al.* Monitoring of Individual Needs in Diabetes (MIND): baseline data from the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) MIND study. *Diabetes Care* 2011;34:601-3.
20. Chawla A, Saha C, Marrero DG. A novel application of the problem areas in diabetes (PAID) instrument to improve glycemic control and patient satisfaction. *Diabetes Educ* 2010;36:337-44.
21. van Bastelaar KMP, Pouwer F, Geelhoed-Duijvestijn PHLM, *et al.* Diabetes-specific emotional distress mediates the association between depressive symptoms and glycemic control in type 1 and type 2 diabetes. *Diabet Med* 2010;27:798-803.
22. Meeuwissen JAC, Hollemann GJM, de Jong FJ, *et al.* Screening and guided self-help intervention for anxiety and depression in patients with type 2 diabetes. A new role for diabetes nurses in primary care? *Eur Diabetes Nurs* 2011;8:47-52.
23. Fleer J, Tovote KA, Keers JC, *et al.* Screening for depression and diabetes-related distress in a diabetes outpatient clinic. *Diabet Med* 2013;30:88-94.
24. Reddy J, Wilhelm K, Campell L. Putting PAID to diabetes-related distress: the potential utility of the problem areas in diabetes (PAID) scale in patients with diabetes. *Psychosomatics* 2013;54:44-51.
25. Schmitt A, Reimer A, Kulzer B, *et al.* How to assess diabetes distress: comparison of the Problem Areas in Diabetes Scale (PAID) and the Diabetes Distress Scale (DDS). *Diabet Med* 2016;33:835-43.
26. Graue M, Haugstvedt A, Wentzel-Larsen T, *et al.* Diabetes-related emotional distress in adults: reliability and validity of the Norwegian versions of the Problem Areas in Diabetes Scale (PAID) and the Diabetes Distress Scale (DDS). *Int J Nurs Stud* 2011;49:174-182.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
27. Staley K. 'Is it worth doing?' Measuring the impact of patient and public involvement in research. *Res Involv Engagem* 2015; 1:6.
28. Polonsky WH, Anderson BJ, Lohrer PA, et al. Assessment of diabetes-related distress. *Diabetes Care* 1995;18:754-60.
29. Welch GW, Jacobson AM, Polonsky WH. The Problem Areas in Diabetes scale: an evaluation of its clinical utility. *Diabetes Care* 1997;20:760-6.
30. Welch G, Weinger K, Anderson B, et al. Responsiveness of the Problem Areas in Diabetes (PAID) questionnaire. *Diabet Med* 2003;20:69-72.
31. Anderson RM, Funnell M. *The Art of Empowerment: Stories and Strategies for Diabetes Educators*. Alexandria, Virginia: American Diabetes Association; 2000.
32. Deci EL, Ryan RM. *Handbook of Self-determination Research*. Rochester, NY: University of Rochester Press; 2002.
33. Zoffmann V, Hörnsten Å, Storbækken S, et al. Translating person-centered care into practice: a comparative analysis of motivational interviewing, illness-integration support, and guided self-determination. *Patient Educ Couns* 2016;99:400-7.
34. Polonsky WH, Fisher L, Psyd JE, et al. Assessing psychosocial distress in diabetes – development of the Diabetes Distress Scale. *Diabetes Care* 2005;28:626-31.
35. Fisher L, Hessler D, Glasgow RE, et al. REDEEM: a pragmatic trial to reduce diabetes distress. *Diabetes Care* 2013;36:2551-8.
36. de Wit M, Pouwer F, Gemke RJJ, et al. Validation of the WHO-5 Well-Being Index in adolescents with type 1 diabetes. *Diabetes Care* 2007;30:2003-6.

- 1
2
3 37. Hajos TR, Pouwer F, Skovlund SE, *et al.* Psychometric and screening properties of the
4 WHO-5 well-being index in adult outpatients with Type 1 or Type 2 diabetes mellitus.
5
6 *Diabet Med* 2013;30:e63-9.
7
8
9
10 38. Topp CW, Østergaard SD, Søndergaard S, *et al.* The WHO-5 Well-Being Index: a
11 systematic review of the literature. *Psychother Psychosom* 2015;84:167-76.
12
13
14 39. Williams GC, McGregor HA, Zeldman A, *et al.* Testing a self-determination theory
15 process model for promoting glycemic control through diabetes self-management.
16
17 *Health Psychol* 2004;23:58-66.
18
19
20
21 40. Williams GC, McGregor HA, King D, *et al.* Variation in perceived competence,
22 glycemic control, and patient satisfaction: relationship to autonomy support from
23 physicians. *Patient Educ Couns* 2005;57:39-45.
24
25
26
27
28 41. Mohn J, Graue M, Assmus J, *et al.* Self-reported diabetes self-management
29 competence and support from healthcare providers in achieving autonomy are
30 negatively associated with diabetes distress in adults with type 1 diabetes. *Diabet Med*
31
32 2015;32:1513-19.
33
34
35
36
37 42. Richards DA, Hallberg IR. Section 2. Investigating feasibility and undertaking pilot
38 testing of complex interventions. *Complex Interventions in Health. An Overview of*
39
40 *Research Methods*. Routledge; 2015:121-82.
41
42
43
44 43. Braun V, Clark V. Using thematic analysis in psychology. *Qual Res Psychol*
45
46 2008;3:77-101.
47
48
49 44. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related
50 quality of life. The remarkable universality of half a standard deviation. *Med Care*
51
52 2003;41:582-92.
53
54
55
56
57
58
59
60

- 1
2
3 45. Carlsen K, Haugstvedt A, Graue M. [PAID as screening and working tool in clinical
4 consultations]. *Norwegian J Clin Nurs* 2015;10:228-37 [in Norwegian].
5
6
7
8 46. Black N, Burke L, Forrest CB, *et al.* Patient-reported outcomes: pathways to better
9 health, better services, and better societies. *Qual Life Res* 2016;25:1103-12.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1.** Key elements in the Medical Research Council's guidance for developing,
4 evaluating and implementing complex interventions (MRC framework). Reproduced
5 from Craig *et al.*[17] with permission.
6
7
8
9

10 **Figure 2.** The study intervention in the DiaPROM trial.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

Figure 1

92x49mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2 The intervention

Figure 2

338x190mm (300 x 300 DPI)

1
2
3
4 SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related
5 documents
6
7



Section/item	Item No	Description	Answer (DiaPROM trial)
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	The title identify design, population, the intervention (use of PROMs) and trial acronym.
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Trial registration number is included (p. 2 and 17).
	2b	All items from the World Health Organization Trial Registration Data Set	All items have been checked and relevant items are included in the protocol.
Protocol version	3	Date and version identifier	Version 10.05.2018
Funding	4	Sources and types of financial, material, and other support	Funding statement is included in the paper (p. 19).
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	Included
	5b	Name and contact information for the trial sponsor	Name of trial sponsor is included (p.17).
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	Included (page 17, 19 and 20).
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	Included in the introduction section (p. 4) and aim section (p. 5) .

	6b	Explanation for choice of comparators	Described (p. 15)
Objectives	7	Specific objectives or hypotheses	An overarching aim and study hypotheses are described in the aim section (p. 5)
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	Described in the method section (starts on p. 5)
Methods: Participants, interventions, and outcomes			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Study setting for feasibility-, pilot- and evaluation studies and participants are described in the method section (starts on p. 5) and in Table 1 (p. 6)
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Described in the method section (starts on p. 5).
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	Described in the method section (starts on p. 5).
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	Described in the method section (p. 14)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	N/A
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	Described in the method section (p. 15)
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	Primary and secondary outcomes, analyses of data from each phases of the study, time point for collecting outcome measures and explanations for clinical relevance is included in the method section (starts on p. 5).

Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Described in the method section (starts on p. 5). A figure describing the steps in the intervention is also included.
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	The rationale for number of participants is described in the method section for the feasibility-, pilot – and evaluation study (starts on p. 5). The sample size calculation for the evaluation study is presented (p. 14)
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	How the feasibility- and pilot study will inform the evaluation study regarding the procedures for among others the participant enrolment is described (p. 13).
Methods: Assignment of interventions (for controlled trials)			
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Included in the method section (p. 14).
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	Described in the method section (p. 14)
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Described in the method section (p. 14)
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Described in the method section (p. 15).
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	The study is not blinded for the participants and the health care providers as stated (p. 15).
Methods: Data collection, management, and analysis			

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Plans for assessments are described in the method section (starts at p. 5). The study evaluation measures are described (p. 9). References to the included instruments are given.
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	Described in the analysis section (p. 16)
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	Data storage is described (p. 17). Data entry is described (p. 8, 12 and 16).
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	Statistical analysis plans for each study phase are included (p. 11, 13 and 16)
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Described (p. 16).
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	Included in the data analysis section (p. 16)
Methods: Monitoring			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	None planned.

	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	None planned.
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	Included in the Ethics and dissemination section (p. 17).
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	Not planned.
Ethics and dissemination			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	Included (p.2 and 17).
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	Described in the Ethics and dissemination section (p. 17).
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	The procedures is described in the method section (starts at p. 4)
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	Described in the Ethics and dissemination section (p. 17).
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	Included (p. 19)
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	Described in the Ethics and dissemination section (p. 17).
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A

Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	Described in the Ethics and dissemination section (p. 17).
	31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Not available in English.
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

BMJ Open

The use of Patient-Reported Outcome Measures (PROMs) in clinical diabetes consultations: study protocol for the DiaPROM randomized controlled trial pilot study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024008.R1
Article Type:	Protocol
Date Submitted by the Author:	01-Nov-2018
Complete List of Authors:	Haugstvedt, Anne; Hogskulen pa Vestlandet, Department of Health and Caring Sciences Hernar, Ingvild; Hogskulen pa Vestlandet, Department of Health and Caring Sciences; Univeristy of Bergen, Department of Global Public Health and Primary Care Strandberg, Ragnhild ; Hogskulen pa Vestlandet, Department of Health and Caring Sciences Richards, David; University of Exeter, Medical School Nilsen, Roy; Hogskulen pa Vestlandet, Department of Health and Caring Sciences Tell, Grethe; University of Bergen, Department of Global Public Health and Primary Care Graue, Marit; Hogskulen pa Vestlandet, Department of Health and Caring Sciences
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Patient-centred medicine
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3
4 The use of Patient-Reported Outcome Measures (PROMs) in
5
6
7
8 clinical diabetes consultations: study protocol for the
9
10
11 DiaPROM randomized controlled trial pilot study.
12
13
14

15 Anne Haugstvedt,¹ Ingvild Hernar,^{1,2,3} Ragnhild B Strandberg,¹ David Richards,⁴

16
17 Roy M Nilsen,¹ Grethe S Tell,² Marit Graue¹

18
19
20
21 ¹Department of Health and Caring Sciences, Western Norway University of Applied Sciences,
22
23 Bergen, Norway

24
25
26 ²Department of Global Public Health and Primary Care, University of Bergen, Bergen,
27
28 Norway

29
30
31 ³Department of Medicine, Haukeland University Hospital, Bergen, Norway

32
33
34 ⁴Institute for Health Research, University of Exeter Medical School, Exeter, UK

35
36
37 Correspondence to: Anne Haugstvedt, Department of Health and Caring Sciences, Western
38
39 Norway University of Applied Sciences, Post Box 7030, N-5020 Bergen, Norway. Tel: +47
40
41 55 58 78 88; Mobile +47 47 82 92 20. E-mail: ahau@hvl.no

42
43
44
45
46 Word count in Abstract: 294

47
48
49
50 Word count in main text: 3795
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction Although diabetes distress is found to be associated with decreased glycaemic control among adults with type 1 diabetes, the psychological and emotional impact of living with the condition is often not recognized and often underreported in diabetes care. Therefore, regular assessment of diabetes distress is recommended. Assessment of diabetes distress using Patient-Reported Outcome Measures (PROMs) in clinical practice has the potential to enhance care for people with diabetes by identifying problems and improving patient-clinician communication. In this study protocol, we describe a pilot randomized controlled trial (RCT) aiming to test the feasibility of all components of an empowerment-based intervention using PROMs as dialogue support in clinical diabetes consultations, and to address the uncertainties associated with running a fully powered evaluation study.

Methods and analysis We will undertake a two arm pilot RCT of an intervention utilising the Problem Areas In Diabetes scale (PAID) in clinical diabetes consultations in order to conclude whether a fully powered trial is appropriate and/or feasible. The study will also include qualitative in-depth interviews with participants and health care personnel. Our objectives are to: 1) evaluate the recruitment procedures and attrition rates; 2) evaluate the performance of the randomization procedure; 3) evaluate the participants' mean scores on the outcome measures before and after the intervention; 4) evaluate if the intervention consultations are acceptable and feasible; and 5) explore patients' and health care personnel's experiences with the use of PAID as dialogue support in clinical diabetes consultations. The quantitative data analysis includes descriptive statistics (frequencies, percentages, means, SD and CI). For the qualitative data, we will perform thematic analysis.

1
2
3 **Ethics and dissemination** Ethical approval has been obtained from the Western Norway
4
5 Regional Committee for Medical and Health Research Ethics (2017/1506/REC west). The
6
7 trial is registered in ClinicalTrials.gov (ID: NCT03471104).
8
9

10 **Keywords** Type 1 diabetes, Diabetes distress, Patient-Reported Outcome Measures
11
12 (PROMs), Complex intervention
13
14
15
16
17
18

19 **Strengths and limitations of the study**

20
21

- 22 • This is a study with the potential to provide new knowledge about the use of Patient-
23
24 Reported Outcome Measures (PROMs) as dialogue support in clinical diabetes
25
26 consultations among patients with type 1 diabetes.
27
28
- 29 • The use of the Medical Research Council's framework as a guide for the development of
30
31 study intervention initiatives like this is a strength because the feasibility and uncertainties
32
33 related to a fully-powered RCT can be illuminated before a resource intensive fully
34
35 powered RCT is conducted.
36
37
- 38 • A key challenge includes possible contamination of the control group although the
39
40 completed PROMs will not be available in the electronic patient records (EPR) of the
41
42 participants in the control group.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

The management of type 1 diabetes (T1D) is complex and people living with the condition need to make numerous daily choices related to their medical treatment.[1, 2] They need to monitor their blood glucose and administer insulin several times each day. The burden of living with T1D remains a challenge despite new insulin types and advances in insulin delivery and glucose monitoring technologies.[3] Many Norwegian adults with T1D do not achieve the recommended treatment goals for glycaemic control.[4, 5] This poor goal attainment might be due to inappropriate choice of insulin regimen for the individual, but research has also shown psychological and emotional aspects are important barriers to satisfactory diabetes self-management.[6]

The psychological and emotional impact of living with diabetes is often unrecognized and/or underreported in diabetes care.[7, 8] Diabetes distress, which reflects the emotional response to the burden, worries, anxieties, frustrations and stressors associated with managing diabetes in everyday life,[9, 10] is found to be associated with decreased glycaemic control.[11, 12] Therefore, regular assessment of diabetes distress is recommended.[13] Such assessment is considered feasible and beneficial to promote the recognition of psychological and emotional issues that affect diabetes self-management.[9, 14]

Collecting Patient-Reported Outcome Measures (PROMs) involves asking people to complete questionnaires concerning the impact of their condition and its treatment on their health.[15] The integration of PROMs in clinical practice has the potential to improve care for people with diabetes and other chronic conditions by screening for and identifying problems, monitoring progress over time, improving patient-clinician communication and enabling people to become more involved in managing their own health.[16] Therefore, the

1
2
3 overarching aim of the Diabetes Patient-Reported Outcome Measures trial (DiaPROM trial) is
4
5 to develop, test and evaluate the effectiveness of a structured empowerment-based
6
7 intervention using PROMs regarding diabetes distress as dialogue support in clinical diabetes
8
9 consultations among adults with T1D. Our proposition is that the DiaPROM intervention
10
11 initiative will reduce diabetes distress and further improve overall well-being, improve
12
13 perceived competence for diabetes management and improve glycaemic control. Based on
14
15 experiences, we also believe that improved focus on the psychological and emotional burden
16
17 of the disease will improve satisfaction with diabetes follow-up. This paper describes the
18
19 protocol for a pilot randomized controlled trial (RCT) to test the feasibility of and
20
21 uncertainties associated with a fully powered evaluation study.
22
23
24
25
26

27 **The development of the DiaPROM trial**

28
29
30 The DiaPROM trial is part of the implementation of PROMs in the Norwegian
31
32 Diabetes Register for Adults (NDR-A). We wanted to design a study to test a method for
33
34 utilizing the PROMs data in clinical diabetes practice. The study is multidisciplinary and
35
36 consists of several interacting components and a number of behaviours required by those
37
38 receiving and delivering the intervention. Thus, we consider the study as a complex
39
40 intervention with a need to develop and test the various components gradually before
41
42 conducting a fully powered RCT. As guidance in this process, we used the Medical Research
43
44 Council's framework (MRC framework) for the evaluation of complex interventions.[17, 18]
45
46
47 The framework describes four important phases in the development, evaluation and
48
49 implementation of a new intervention initiative: (1) the development phase, (2) the feasibility
50
51 and piloting phase, (3) the evaluation phase and (4) the implementation phase (figure 1).
52
53
54
55
56
57
58
59
60

1
2
3 The development of the DiaPROM trial took place during 2016 and 2017. Initially,
4 the essential tasks were to determine which PROMs to include and how patients should
5 complete the PROMs.
6
7
8
9

10 *PROMs to include*

11
12
13
14 We reviewed the literature to identify published articles on the use of PROMs as
15 dialogue support in clinical diabetes practice. We wanted to identify the most common used
16 PROMs to measure diabetes distress. We recognized that studies have primarily used PROMs
17 to evaluate interventions' effects; relatively few publications have reported on the use of
18 PROMs in clinical diabetes care. We did identify, however, a multi-centre study across eight
19 countries that had tested the feasibility and impact of a procedure for implementing PROMs
20 in routine diabetes care.[14, 19] This computer-assisted "Monitoring of Individual Needs in
21 Diabetes" procedure aimed to improve recognition and management of the psychological
22 needs of patients with diabetes in routine care. Regular assessment of psychological needs
23 was implemented as part of the annual review in diabetes clinics. The assessment included
24 diabetes distress measured by the Problem Areas in Diabetes (PAID) scale. Accordingly,
25 Schmitt *et al.*[20] emphasize the necessity of a justified choice of measurement and
26 recommend the use of the PAID when the clinical purpose is to bear in mind a variety of
27 emotional concerns related to living with diabetes. Some other studies have reported PAID as
28 an appropriate instrument for use in clinical diabetes consultations, as well.[21-25] The scale
29 may contribute to improved communication by making the dialogue between health care
30 providers and patients more therapeutic and goal oriented.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patient and public involvement

Involving health service users throughout all phases of a study is important to provide insight into patients' perspectives and ensure that the research focuses on issues relevant for the health service users and the public.[26, 27] Patient and public involvement (PPI) is also useful in terms of shaping the research processes.[26] In this study, we used the GRIPP2 short form as guidance for including and reporting PPI.[27] To include the voice of the health service users throughout the study, two people with diabetes have been included in the DiaPROM project group, both experienced with PPI and research. They will contribute to all phases of the study. Furthermore, we have included additional people with diabetes to share their views on the various phases of the study, recruited mainly from national and local diabetes associations.

A crucial question when we considered which PROMs to include in the study, was what adult people with T1D perceived as the most important and relevant aspects to emphasize in diabetes follow-up. Thus, in parallel with the literature review, we consulted the health service users. In addition to the health service users in the project group, we met the leader of the Norwegian Diabetes Association and a group of four representatives from the local diabetes association (two with T1D and two parents of children with T1D where one had type 2 diabetes herself). First, we used open question to the health service users to determine which topics they perceived as important and relevant to include in a set of PROMs. After an open discussion, we asked them to review several generic instruments (e.g. World Health Organization's 5-item well-being index (WHO-5), RAND-12 Health Status Inventory (RAND-12), Patient Activation Measure (PAM)) and diabetes-specific instruments (e.g. PAID, Diabetes Distress Scale (DDS), Perceived Competence for Diabetes Scale (PCDS)). The user representatives considered the advantages and shortcomings of using the 20

1
2
3 statements in PAID as dialogue support in the intervention. They found the instrument
4
5 relevant and suitable to be used in the intervention.
6
7

8 9 *The PAID*

10
11
12 Based on the literature review and in accordance with the input from the health service
13
14 users, we chose the PAID scale for use in the study intervention. The participants' PAID
15
16 scores will constitute the basis for the dialogue in the clinical consultations. The scale was
17
18 developed to gain insight into the breadth of emotional responses to living with diabetes, and
19
20 consists of 20 statements regarding diabetes distress (e.g. "feeling constantly concerned about
21
22 food and eating", "worrying about low blood sugar reactions").[28-30] The scores are on a 5-
23
24 point Likert scale from 0 (not a problem) to 4 (serious problem). An item score of 3
25
26 (somewhat serious problem) or 4 (serious problem) indicates moderate to serious diabetes
27
28 distress related to the specific item. Scale scores are transformed to a 0-100 scale, with higher
29
30 scores indicating greater distress, and a PAID total score >40 suggests serious diabetes-related
31
32 distress. To identify both moderate and serious distress, we defined scores of concern as
33
34 PAID total scores ≥ 30 or single item scores of 3 or 4. The scale has been translated into
35
36 several languages, including Norwegian.[31]
37
38
39
40
41
42

43 *Method for completing PROMs*

44
45
46 The literature describes various methods for administration of PROMs such as paper-
47
48 based self-administration at home or in the clinic, interviews by telephone or personal
49
50 meetings, computer-assisted self-administration in the clinic or mail- or web-based
51
52 administration from patients' homes.[16] In our study, we decided on computer-assisted
53
54 administration on a touchscreen computer in the outpatient clinic. Using this method has
55
56 advantages, such as efficient and simultaneous data entry and minor privacy challenges.
57
58
59
60

Feasibility study

We conducted a feasibility study in 2017 to examine the technical and practical feasibility of collecting PROMs on a touchscreen computer in the outpatient clinic, and evaluate the participants' perceived understanding and relevance of the items in the PAID and the included outcome measures. We also evaluated the acceptability of completing PROMs annually. Field observations and comments from the participants provided data on the technical and practical procedures. Sixty-nine individuals with T1D ≥ 40 years participated in the study and 83% of them reported that, to a high or a very high degree, they would be positive about an annual completion of PROMs. However, almost 20% of 137 invited patients did not show up at the clinic (change of appointments, sick, no reason given), and most of the invited ones did not go directly to the computer on arrival at the clinic as instructed in the information sheet. Thus, we developed clearer information and procedures for the pilot study to avoid loss of potential participants among those invited. Further analyses of the results from the feasibility study are ongoing, and we plan to publish these in a separate article.

Aim

The purpose of the pilot RCT reported here is to test the feasibility of the proposed DiaPROM trial components and address the uncertainties associated with running a fully powered RCT, in order to conclude whether such a trial is appropriate and/or feasible. Our objectives are to:

1. evaluate the recruitment procedures and attrition rates;
2. evaluate the performance of the randomization procedure;
3. evaluate the participants' mean scores on the outcome measures before and after the intervention;

4. evaluate if the intervention consultations are acceptable and feasible; and
5. explore patients' and health care personnel's experiences with the use of PAID as dialogue support in clinical diabetes consultations.

METHODS AND ANALYSIS

We will undertake a two arm pilot RCT with embedded qualitative study on participants' and health care providers' views of the DiaPROM intervention initiative. We report our protocol here using the SPIRIT checklist (<http://www.spirit-statement.org/wp-content/uploads/2013/01/SPIRIT-Checklist-download-8Jan13.pdf>).

Participants and eligibility criteria

As recommended for pilot RCTs,[32] we will include 80 participants: 40 in the intervention group and 40 controls. Participants will have T1D for at least 1 year and be aged ≥ 18 to < 40 years. We will exclude people who are unable to read or complete the PROMs on the touchscreen computer. Furthermore, we will exclude pregnant woman, patients with known and recorded cognitive deficiency (e.g. Down's syndrome, Alzheimer), severe somatic comorbidity (e.g. end stage renal disease, severe heart failure, severe cancer), and/or a major psychiatric diagnosis (e.g. severe depression, bipolar disorder, schizophrenia) as diabetes distress is often neither ethical nor possible to discuss with these group of patients. Eligible participants will receive information and consent forms by regular mail before their annual diabetes consultation at the clinic. The information form will include information about the possibility to withdraw from the study at any time point without consequences.

Randomization procedure and allocation concealment

We will randomize eligible and consenting participants, using computer-generated block randomization at the patient level, stratified for gender, immediately after the participants have completed both the PAID and the self-reported outcome measures. When participants complete the measures on the touchscreen computer in the outpatient clinic, they will receive an individual four-character code. When the physician downloads the PROMs data using the code, a concealed computerized allocation will take place. Information about which group the person is allocated to will appear on the computer screen and the physician will inform the participant immediately. It is not possible to blind either participants or health care providers.

Trial intervention

After participants have completed the PAID scale, physicians download the scores into the participants' electronic patient record (EPR) as part of the annual consultation (figure 2). Physicians then review and discuss the PAID scores briefly with participants. Participants with one or more single PAID item(s) score of 3 or 4 (somewhat serious or serious problem), or PAID total score ≥ 30 , will be referred to additional diabetes nurse consultations. Participants with lower scores will receive regular follow-up according to usual clinical protocols.

Additional nurse follow-up will consist of at least two consultations. The first will take place within four weeks after randomization, and the second within a further three months. After the second nurse consultation, the nurse and the participant will agree any further follow-up until the next annual consultation with the physician. Diabetes nurses will review PAID scores and discuss the reported problem areas and distress with participants by

1
2
3 following a communication manual based on key elements from empowerment theory and
4 self-determination theory, such as empathetic communication and autonomy support.[33-35]
5
6 These communication skills involve “active listening”, “asking open questions”,
7
8 “responding”, “summing up” and “agreeing on goals and actions to take”. Nurses will record
9
10 their work on participants’ problem areas, goals and actions. The intervention will last for a
11
12 maximum of one year, until the next annual consultation.
13
14
15
16
17

18 **Control procedure**

19
20
21 The control group will receive “care as usual” which does not include a structured
22
23 focus on psychological and emotional diabetes distress. For most patients the annual
24
25 consultation normally constitute “care as usual”. Although all participants will complete the
26
27 PAID before randomization, for control participants the scores will not be accessible to
28
29 clinicians in the EPR until the study is completed. For ethical reasons, we will not prevent
30
31 physicians discussing psychological or emotional issues with participants in the control group
32
33 if participants specifically raise such an issue. Unlike participants in the intervention group,
34
35 such discussions will not be structured with reference to PAID data. We will identify to what
36
37 extent such discussions have taken place by reviewing participants’ EPR.
38
39
40
41
42
43

44 **Training of health care personnel**

45
46
47 Before the study commences, we will have a one-hour meeting with the participating
48
49 physicians, and they will be trained in how to download the PAID scores into the EPR and
50
51 how to briefly discuss the scores in the annual consultations. Further, they will get both oral
52
53 information and written instructions regarding the interpretation of the PAID scores including
54
55 instructions on the criteria for referral of participants to extra follow-up by the diabetes
56
57 nurses. Nurses will get both oral and written information and a 2 x 1 hour training in how to
58
59
60

1
2
3 interpret scores and discuss the reported problem areas, how to follow the communication
4 manual in the consultations, and how to agree upon goals and actions to take with the
5 participants.
6
7
8
9

10 **Data collection and outcome measures**

11
12
13
14
15 All participants (both intervention and control groups) will complete the outcome
16 measures electronically before the annual consultation at baseline and after 12 months. After
17 the annual consultation, the participants will complete a paper-based questionnaire about their
18 experience and satisfaction with the diabetes follow-up. We will evaluate the recruitment
19 procedures and attrition rates by observing and monitoring number of eligible participants
20 invited, number of invited people declining participation, number of people who attended the
21 clinic, number of intervention participants attended the nurse consultations, and number of
22 consultations conducted. We will also observe and document the technical performance of the
23 randomization procedure. Finally, we will document all types of contacts between participants
24 and the diabetes outpatient clinic for all participants throughout the study period.
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 To describe the study sample and evaluate the technical procedure of data retrieval
40 from EPR, we will perform a computerized retrieval of the following variables from the
41 participants' EPR: sex, age, ethnicity, body mass index, diabetes duration, HbA_{1c} (secondary
42 outcome), insulin regimen, insulin doses, severe hypoglycaemic episodes needing assistance
43 in the past year, hospitalizations, co-morbidities and diabetes late complications.
44
45
46
47
48
49
50

51 The outcome measures to evaluate the effect of the intervention in the evaluation
52 phase of the study (phase 3), were chosen based on a literature review and considerations
53 among the researchers and the health service users. We decided upon the DDS as primary
54 outcome. DDS measures diabetes distress and contains 17 items and 4 subscales: emotional
55
56
57
58
59
60

1
2
3 burden (5 items), physician-related distress (4 items), regimen distress (5 items) and diabetes-
4 related interpersonal distress (3 items).[36] The scores are on a 6-point Likert scale from 1
5 (not a problem) to 6 (serious problem) with mean total or subscale score from 1 to 6.[37]
6
7
8 Total or subscale scores >3 are defined as high levels of distress. The DDS has previously
9 shown satisfactory psychometric properties to map diabetes distress, and might have
10 advantages for use as outcome measure in clinical trials because it contributes to identify sub-
11 domains of distress.[11, 20, 31] To measure the secondary outcomes, overall well-being and
12 perceived diabetes competence, we have included the WHO-5[38-40] and the PCDS.[41-43]
13
14 We will use HbA1c as the target for glycaemic control.

15
16
17 We will invite all participants from the intervention group and all health care
18 personnel (physicians and diabetes nurses) participating in the intervention group to
19 individual in-depth interviews to collect qualitative data on their experiences with the
20 intervention, including the use of PAID as dialogue support in clinical consultations. This will
21 provide a sample of about 15-20 participants and 10-15 health care personnel. All interviews
22 will be conducted at the outpatient clinic, and will be audio recorded after obtaining consent
23 from participants.
24
25

26 27 28 **Data analysis**

29
30 We will use Stata SE 15 for Windows for all statistical analyses,[44] and for data entry
31 range checks for data values will be performed. We will report the recruitment of participants
32 and the number of trial dropouts descriptively (frequencies and percentages). Further, we will
33 report the means, SD and CI of the DDS and the other outcome measurements before and
34 after the intervention period for both the intervention and control groups. As the study is a
35 pilot and the sample size is small, we will not perform inferential statistics and analyze
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 between group calculations. The participants' PAID scores will be analysed descriptively
4
5 (mean, SD), as well.
6
7

8
9 We will transcribe verbatim and analyse participants' and health care personnel's
10
11 experiences with the intervention, by using thematic analysis.[45] Thematic analysis is a
12
13 flexible qualitative method without any specific theoretical foundation and consists of six
14
15 steps: 1) transcribing, reading and re-reading, 2) generating initial codes, 3) searching for
16
17 themes, 4) reviewing themes, 5) defining and naming the themes, and 6) producing the report.
18
19

20 21 **ETHICS AND DISSEMINATION** 22 23

24
25
26 The Norwegian Regional Committee for Medical and Health Research Ethics has
27
28 approved the study (2017/1506/REK west). Haukeland University Hospital, Bergen, Norway
29
30 is the responsible research institution (trial sponsor) where the study data will be stored on a
31
32 secure research server. In order to protect confidentiality, names of the potential and enrolled
33
34 participants will be stored separate from the other study data. Only the principle investigator
35
36 and other clearly identified members of the project group have access to the study data. If
37
38 important protocol modifications happen, this will be communicated to the ethic committee
39
40 and ClinicalTrials.gov. Further information can be obtained from ClinicalTrials.gov,
41
42 registration number NCT03471104.
43
44
45
46

47
48 Completing the PROMs may activate latent psychological or psychosocial problems
49
50 and negative feelings. To care for any participants in the control group reporting worryingly
51
52 high levels of distress (e.g. above cut points for severe levels of distress measured by PAID
53
54 and/or DDS), the research team will continuously review the reported distress levels. We will
55
56 discuss potential needs for more intensive care or referral to psychological or psychiatric
57
58
59
60

1
2
3 follow-up for those reporting worryingly levels of distress with the physicians and diabetes
4
5 nurses.
6
7

8
9 We will present the findings of the study phases at national and international
10 conferences and submit manuscripts to peer-reviewed journals and popular science journals.
11
12 Further, we will also publish the findings in popular science journals, public newspapers and
13
14 journals for relevant user groups. One of the health service users will participate in the writing
15
16 and publication process.
17
18
19

20 21 **DISCUSSION** 22 23

24
25 In the pilot RCT study described in this protocol, we aim to test the feasibility of, and
26
27 address the clinical and methodological uncertainties associated with running a fully powered
28
29 RCT testing the effect of an intervention incorporating the use of PAID to decrease diabetes
30
31 distress among people with T1D. The study will provide knowledge on the use of PAID in
32
33 clinical diabetes practice, although the purpose primarily is to prepare the ground for the
34
35 design and conduct of a full powered RCT.
36
37
38
39

40
41 Diabetes distress has been shown to be a barrier for satisfactory glycaemic control,
42
43 [11, 12] and a more structured focus on diabetes distress, may have the potential to improve
44
45 long-term health for people with T1D by reducing the distress and improving glycaemic
46
47 control. A previous literature review by Carlsen *et al.*[46] found that the use of PAID could
48
49 benefit patients but emphasized the need for follow-up studies to evaluate whether the PAID
50
51 should be implemented in routine diabetes care to enhance a more structured focus on
52
53 diabetes distress. The choice of utilizing PAID as dialogue support in the intervention and the
54
55 DDS as the primary outcome measure is in accordance with previous research. Both
56
57 instruments have previously shown satisfactory psychometric properties to map individual
58
59
60

1
2
3 levels of diabetes distress, but it has been claimed that the PAID has advantages for use in
4 clinical practice and that the DDS have advantages for use in clinical trials, because it also
5 contributes to identifying sub-domains of distress.[11, 20, 31]
6
7
8
9

10 11 **Strengths and limitations** 12

13
14 The use of the MRC framework is a strength in the development of this study, because
15 it includes several complex and interacting components that need to be considered and tested
16 with the purpose to reveal uncertainties before conducting a fully powered RCT. In addition,
17 the use of the GRIPP2 short form to guide the PPI throughout all phases of the development
18 of the intervention initiative is considered a strength. The health service users included in the
19 project have influenced among others the choice of PROMs, the choice of the theoretical
20 foundation for the intervention, and the discussions related to the qualitative component of the
21 study.
22
23
24
25
26
27
28
29
30
31
32

33 We have included primarily disease-specific outcome measures, but also one generic
34 PROM (WHO-5). Disease-specific PROMs are used to capture information that is most
35 pertinent to particular patient groups, but they might miss domains affecting the patient that
36 are unrelated to their disease.[16, 47] Generic instruments may capture broad dimensions of
37 health and allow for comparisons between populations but might not be sensitive to changes
38 in disease-specific health domains over time or in relation to interventions.[15]
39
40
41
42
43
44
45
46
47

48 The fact that the control group in the study will also complete the PAID and the
49 evaluation PROMs before the annual diabetes consultation, and that the same physicians meet
50 participants from both the intervention and the control groups might lead to intervention
51 contamination challenges. This might be a challenge although the scores will not be
52 accessible in the electronic patient records of participants in the control group.
53
54
55
56
57
58
59
60

Acknowledgements

Thanks to the Norwegian Nurses Association, the Norwegian Diabetes Association and Western Norway University of Applied Sciences for funding the study. Thanks also to the Norwegian Diabetes Register for Adults and DIPS AS for fruitful collaboration. Further, we thank all the health care personnel and the health care service user representatives involved in the study. Thanks also to senior research fellow Peter Craig for giving us the permission to reproduce the figure describing the study phases in the development of a complex intervention.

Contributors

AH and MG applied for funding of the trial. AH, IH, MG and RBS designed the study with involvement of GST, DR and RMN. AH wrote the first draft of the study protocol. All other authors have edited and critically reviewed the manuscript, and all authors read and approved the final version.

Funding

The study is funded by the Norwegian Nurse Association, Western Norway University of Applied Sciences, the Norwegian Diabetes Association and the Norwegian Diabetes Register for Adults. The first two funded a postdoctoral position and a PhD position, respectively. The last two contributed with running funds.

Competing interests

None declared.

Patient consent

There is no patient data included in this report.

REFERENCES

1. American Association of Diabetes Educators (ADE). AADE7 Self-Care Behaviors. *Diabetes Educ* 2008;34:445-9.
2. American Diabetes Association (ADA). Introduction: standards of medical care in diabetes. *Diabetes Care* 2018;41(Suppl 1):1-2. Available from: <https://doi.org/10.2337/dc18-Sint01> (Accessed Jan 22, 2018).
3. Jones A, Vallis M, Pouwer F. If it does not significantly change HbA 1c levels why should we waste time on it? A plea for the prioritization of psychological well-being in people with diabetes. *Diabet Med* 2015;32:155-63.
4. Cooper JG, Claudi T, Thordarson HB, *et al.* Treatment of type 1 diabetes in the specialist health service-data from the Norwegian Diabetes Register for Adults. *J Norwegian Med Assoc* 2013;133:2257.
5. Carlsen S, Skrivarhaug T, Thue G, Cooper JG, Goransson L, Lovaas K, *et al.* Glycemic control and complications in patients with type 1 diabetes - a registry-based longitudinal study of adolescents and young adults. *Pediatr Diabetes* 2017;18:188-95.
6. Pouwer F, Nefs G, Nouwen A. Adverse effects of depression on glycemic control and health outcomes in people with diabetes: a review. *Endocrinol Metab Clin North Am* 2013;42:529-44.

- 1
2
3 7. Pouwer F, Beekman ATF, Lubach C, *et al.* Nurses' recognition and registration of
4 depression, anxiety and diabetes-specific emotional problems in outpatients with
5 diabetes mellitus. *Patient Educ Couns* 2006;60:235-40.
6
7
- 8
9
10 8. Peyrot M, Rubin RR, Lauritzen T, *et al.* Psychosocial problems and barriers to
11 improved diabetes management: results of the Cross-National Diabetes Attitudes,
12 Wishes and Needs (DAWN) Study. *Diabet Med* 2005;22:1379-85.
13
14
- 15 9. Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in
16 patients with diabetes: a call for greater clarity and precision. *Diabet Med*
17 2014;31:764-72.
18
19
- 20 10. Snoek FJ, Bremmer MA, Hermanns N. Constructs of depression and distress in
21 diabetes: time for an appraisal. *Lancet Diabetes Endocrinol* 2015;3:450-60.
22
23
- 24 11. Strandberg RB, Graue M, Wentzel-Larsen T, *et al.* Longitudinal relationship between
25 diabetes-specific emotional distress and follow-up HbA_{1c} in adults with Type 1
26 diabetes mellitus. *Diabet Med* 2015;32:1304-10.
27
28
- 29 12. Fisher L, Hessler D, Polonsky W, *et al.* Diabetes distress in adults with type 1
30 diabetes: Prevalence, incidence and change over time. *J Diabetes Complications*
31 2016;30:1123-8.
32
33
- 34 13. International Diabetes Federation. *International Diabetes Federation Diabetes Atlas*
35 [Online]. 8th ed. International Diabetes Federation; 2017. Available from:
36 <http://www.diabetesatlas.org/resources/2017-atlas.html> (accessed Jan 15, 2018).
37
38
- 39 14. Snoek FJ, Kersch NY, Eldrup E, *et al.* Monitoring of Individual Needs in Diabetes
40 (MIND)-2: follow-up data from the cross-national Diabetes Attitudes, Wishes, and
41 Needs (DAWN) MIND study. *Diabetes Care* 2012;35:2128-32.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 15. Greenhalgh J, Dalkin S, Gooding K, *et al.* Functionality and feedback: a realist
4
5 synthesis of the collation, interpretation and utilisation of patient-reported outcome
6
7 measures data to improve patient care. *Health Serv Deliv Res* 2017;5.2.
- 8
9
10
11 16. Snyder CF, Aaronson NK, Choucair AK, *et al.* Implementing patient-reported
12
13 outcomes assessment in clinical practice: a review of the options and considerations.
14
15 *Qual Life Res* 2012;21:1305-14.
- 16
17
18 17. Craig P, Dieppe P, Macintyre S, *et al.* Developing and evaluating complex
19
20 interventions: the new Medical Research Council guidance. *BMJ* 2008;337:979-83.
- 21
22
23 18. Craig, P. Developing and evaluating complex interventions: reflections on the 2008
24
25 MRC guidance. *Int J Nurs Stud* 2013;50:585-92.
- 26
27
28 19. Snoek, FJ, Kersch NY, Eldrup E, *et al.* Monitoring of Individual Needs in Diabetes
29
30 (MIND): baseline data from the cross-national Diabetes Attitudes, Wishes, and Needs
31
32 (DAWN) MIND study. *Diabetes Care* 2011;34:601-3.
- 33
34
35 20. Schmitt A, Reimer A, Kulzer B, *et al.* How to assess diabetes distress: comparison of
36
37 the Problem Areas in Diabetes Scale (PAID) and the Diabetes Distress Scale (DDS).
38
39 *Diabet Med* 2016;33:835-43.
- 40
41
42 21. Chawla A, Saha C, Marrero DG. A novel application of the problem areas in diabetes
43
44 (PAID) instrument to improve glycemic control and patient satisfaction. *Diabetes*
45
46 *Educ* 2010;36:337-44.
- 47
48
49 22. van Bastelaar KMP, Pouwer F, Geelhoed-Duijvestijn PHLM, *et al.* Diabetes-specific
50
51 emotional distress mediates the association between depressive symptoms and
52
53 glycemic control in type 1 and type 2 diabetes. *Diabet Med* 2010;27:798-803.
- 54
55
56
57
58
59
60

- 1
2
3 23. Meeuwissen JAC, Hollemann GJM, de Jong FJ, *et al.* Screening and guided self-help
4 intervention for anxiety and depression in patients with type 2 diabetes. A new role for
5 diabetes nurses in primary care? *Eur Diabetes Nurs* 2011;8:47-52.
6
7
- 8
9
10 24. Fler J, Tovote KA, Keers JC, *et al.* Screening for depression and diabetes-related
11 distress in a diabetes outpatient clinic. *Diabet Med* 2013;30:88-94.
12
13
- 14
15 25. Reddy J, Wilhelm K, Campell L. Putting PAID to diabetes-related distress: the
16 potential utility of the problem areas in diabetes (PAID) scale in patients with diabetes.
17 *Psychosomatics* 2013;54:44-51.
18
19
- 20
21 26. Staley K. 'Is it worth doing?' Measuring the impact of patient and public involvement
22 in research. *Res Involv Engagem* 2015; 1:6.
23
24
- 25
26 27. Staniszewska S, Brett J, Simera I, *et al.* GRIPP2 reporting checklists: tools to improve
27 patient and public involvement in research. *BMJ* 2017;358:j3453.
28
29
- 30
31 28. Polonsky WH, Anderson BJ, Lohrer PA, *et al.* Assessment of diabetes-related distress.
32 *Diabetes Care* 1995;18:754-60.
33
34
- 35
36 29. Welch GW, Jacobson AM, Polonsky WH. The Problem Areas in Diabetes scale: an
37 evaluation of its clinical utility. *Diabetes Care* 1997;20:760-6.
38
39
- 40
41 30. Welch G, Weinger K, Anderson B, *et al.* Responsiveness of the Problem Areas in
42 Diabetes (PAID) questionnaire. *Diabet Med* 2003;20:69-72.
43
44
- 45
46 31. Graue M, Haugstvedt A, Wentzel-Larsen T, *et al.* Diabetes-related emotional distress
47 in adults: reliability and validity of the Norwegian versions of the Problem Areas in
48 Diabetes Scale (PAID) and the Diabetes Distress Scale (DDS). *Int J Nurs Stud*
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 32. Richards DA, Hallberg IR. Section 2. Investigating feasibility and undertaking pilot
4 testing of complex interventions. *Complex Interventions in Health. An Overview of*
5
6 *Research Methods*. Routledge; 2015:121-82.
7
8
9
10
11 33. Anderson RM, Funnell M. *The Art of Empowerment: Stories and Strategies for*
12 *Diabetes Educators*. Alexandria, Virginia: American Diabetes Association; 2000.
13
14
15 34. Deci EL, Ryan RM. *Handbook of Self-determination Research*. Rochester, NY:
16 University of Rochester Press; 2002.
17
18
19
20 35. Zoffmann V, Hörnsten Å, Storbækken S, *et al*. Translating person-centered care into
21 practice: a comparative analysis of motivational interviewing, illness-integration
22 support, and guided self-determination. *Patient Educ Couns* 2016;99:400-7.
23
24
25
26
27 36. Polonsky WH, Fisher L, Psyd JE, *et al*. Assessing psychosocial distress in diabetes –
28 development of the Diabetes Distress Scale. *Diabetes Care* 2005;28:626-31.
29
30
31
32 37. Fisher L, Hessler D, Glasgow RE, *et al*. REDEEM: a pragmatic trial to reduce diabetes
33 distress. *Diabetes Care* 2013;36:2551-8.
34
35
36
37
38 38. de Wit M, Pouwer F, Gemke RBJ, *et al*. Validation of the WHO-5 Well-Being Index
39 in adolescents with type 1 diabetes. *Diabetes Care* 2007;30:2003-6.
40
41
42
43 39. Hajos TR, Pouwer F, Skovlund SE, *et al*. Psychometric and screening properties of the
44 WHO-5 well-being index in adult outpatients with Type 1 or Type 2 diabetes mellitus.
45 *Diabet Med* 2013;30:e63-9.
46
47
48
49
50 40. Topp CW, Østergaard SD, Søndergaard S, *et al*. The WHO-5 Well-Being Index: a
51 systematic review of the literature. *Psychother Psychosom* 2015;84:167-76.
52
53
54
55
56
57
58
59
60

- 1
2
3 41. Williams GC, McGregor HA, Zeldman A, et al. Testing a self-determination theory
4 process model for promoting glycemic control through diabetes self-management.
5
6 *Health Psychol* 2004;23:58-66.
7
8
9
10 42. Williams GC, McGregor HA, King D, et al. Variation in perceived competence,
11 glycemic control, and patient satisfaction: relationship to autonomy support from
12 physicians. *Patient Educ Couns* 2005;57:39-45.
13
14
15
16
17 43. Mohn J, Graue M, Assmus J, et al. Self-reported diabetes self-management
18 competence and support from healthcare providers in achieving autonomy are
19 negatively associated with diabetes distress in adults with type 1 diabetes. *Diabet Med*
20 2015;32:1513-19.
21
22
23
24
25
26
27 44. StataCorp LLC. STATA Data Analysis and Statistical Software. Stata SE 15 ed.
28 College Station, Texas, USA: StataCorp LLC; 2018.
29
30
31
32 45. Braun V, Clark V. Using thematic analysis in psychology. *Qual Res Psychol*
33 2008;3:77-101.
34
35
36
37 46. Carlsen K, Haugstvedt A, Graue M. [PAID as screening and working tool in clinical
38 consultations]. *Norwegian J Clin Nurs* 2015;10:228-37 [in Norwegian].
39
40
41
42 47. Black N, Burke L, Forrest CB, et al. Patient-reported outcomes: pathways to better
43 health, better services, and better societies. *Qual Life Res* 2016;25:1103-12.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1.** Key elements in the Medical Research Council's guidance for developing,
4
5 evaluating and implementing complex interventions (MRC framework). Reproduced
6
7 from Craig *et al.*[17] with permission.
8
9

10
11 **Figure 2.** The study intervention in the DiaPROM trial.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

Figure 1

92x49mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2 The intervention

Figure 2

338x190mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents

Section/item	Item No	Description	Answer (DialPROM trial)
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	The title identify design, population, the intervention (use of PROMs) and trial acronym.
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Trial registration number is included (p. 2 and 15).
	2b	All items from the World Health Organization Trial Registration Data Set	All items have been checked and relevant items are included in the protocol.
Protocol version	3	Date and version identifier	Version 25.10.2018
Funding	4	Sources and types of financial, material, and other support	Funding statement is included in the paper (p. 18).
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	Included
	5b	Name and contact information for the trial sponsor	Name of trial sponsor is included (p.18).
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	Included (page 15 and 18).
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	Described in the introduction section (p. 4-5) and aim section (p. 9-10) .

	6b	Explanation for choice of comparators	Described (p. 11-12)
Objectives	7	Specific objectives or hypotheses	An overarching aim of the DiaPROM trial are described (p. 5), and the aim of the present pilot RCT are described in the aim section (p. 9-10)
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	Described in the methods section (starts on p. 10)
Methods: Participants, interventions, and outcomes			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Study setting and participants for the pilot study are described in the methods section (starts on p. 10).
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Described in the methods section (starts on p. 10).
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	Described in the methods section (starts on p. 10).
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	Described in the methods section (p. 13) and in the ethic section (p. 15-16).
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	N/A
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	Described in the methods section (p. 10-13)

Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	Primary and secondary outcomes for the forthcoming fully powered RCT are described (p. 5). The objectives for the present pilot RCT are described (p. 9-10), and the analyses of data (p. 14-15), time point for collecting outcome measures (p. 13-14), and explanations for clinical relevance of the DiaPROM trial (p. 4-5 and 16), as well.
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Described in the methods section (starts on p. 10). A figure describing the steps of the intervention is also included.
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	The rationale for number of participants is described in the methods section (p. 10).
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	Not relevant for a pilot study
Methods: Assignment of interventions (for controlled trials)			
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Included in the methods section (p. 11).
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	Described in the methods section (p. 11)
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Described in the methods section (p. 11)
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Described in the methods section (p. 11).

	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	The study is not blinded for the participants and the health care providers as stated (p. 11).
Methods: Data collection, management, and analysis			
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Plans for assessment and included measures are described in the methods section (p. 13-14). References to the included instruments are given.
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	The relevant information for a pilot RCT is described in the methods section (p. 13-14)
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	Data storage is described (p. 15). Data entry is described (p. 14). Reference to where details of data management procedures can be found is described (p. 12 and 15)
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	Statistical analysis plans for both quantitative and qualitative data are included (p. 14-15)
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	N/A for a pilot study
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	N/A for a pilot study
Methods: Monitoring			

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	None planned.
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	None planned.
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	Included in the ethics and dissemination section (p. 15-16).
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	Not planned.
Ethics and dissemination			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	Included (p.2 and 16)
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	Described in the ethics and dissemination section (p. 15-16).
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	Described in the method section (starts on p. 10)
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	Described in the ethics and dissemination section (p. 15-16).

1 2 3 4	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	Included (p. 18)
5 6 7	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	Described in the ethics and dissemination section (p. 15-16).
8 9 10	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
11 12 13 14 15 16	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	Described in the ethics and dissemination section (p. 15-16).
17 18 19		31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
20 21 22		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A
23 24	Appendices			
25 26 27	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Not available in English.
28 29 30 31 32	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A

33 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the
 34 protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)"
 35 license.
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46

BMJ Open

The use of Patient-Reported Outcome Measures (PROMs) in clinical diabetes consultations: study protocol for the DiaPROM randomized controlled trial pilot study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024008.R2
Article Type:	Protocol
Date Submitted by the Author:	28-Nov-2018
Complete List of Authors:	Haugstvedt, Anne; Hogskulen pa Vestlandet, Department of Health and Caring Sciences Hernar, Ingvild; Hogskulen pa Vestlandet, Department of Health and Caring Sciences; Univeristy of Bergen, Department of Global Public Health and Primary Care Strandberg, Ragnhild ; Hogskulen pa Vestlandet, Department of Health and Caring Sciences Richards, David; University of Exeter, Medical School Nilsen, Roy; Hogskulen pa Vestlandet, Department of Health and Caring Sciences Tell, Grethe; University of Bergen, Department of Global Public Health and Primary Care Graue, Marit; Hogskulen pa Vestlandet, Department of Health and Caring Sciences
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Patient-centred medicine
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3
4 The use of Patient-Reported Outcome Measures (PROMs) in
5
6
7
8 clinical diabetes consultations: study protocol for the
9
10
11 DiaPROM randomized controlled trial pilot study.
12
13
14

15 Anne Haugstvedt,¹ Ingvild Hernar,^{1,2,3} Ragnhild B Strandberg,¹ David Richards,⁴
16
17 Roy M Nilsen,¹ Grethe S Tell,² Marit Graue¹
18
19

20
21 ¹Department of Health and Caring Sciences, Western Norway University of Applied Sciences,
22
23 Bergen, Norway
24
25

26 ²Department of Global Public Health and Primary Care, University of Bergen, Bergen,
27
28 Norway
29
30

31 ³Department of Medicine, Haukeland University Hospital, Bergen, Norway
32
33

34 ⁴Institute for Health Research, University of Exeter Medical School, Exeter, UK
35
36

37 Correspondence to: Anne Haugstvedt, Department of Health and Caring Sciences, Western
38
39 Norway University of Applied Sciences, Post Box 7030, N-5020 Bergen, Norway. Tel: +47
40
41 55 58 78 88; Mobile +47 47 82 92 20. E-mail: ahau@hvl.no
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word count in Abstract: 297

Word count in main text: 4246

ABSTRACT

Introduction Although diabetes distress is found to be associated with decreased glycaemic control among adults with type 1 diabetes, the psychological and emotional impact of living with the condition is often not recognized and often underreported in diabetes care. Therefore, regular assessment of diabetes distress is recommended. Assessment of diabetes distress using Patient-Reported Outcome Measures (PROMs) in clinical practice has the potential to enhance care for people with diabetes by identifying problems and improving patient-clinician communication. In this study protocol, we describe a pilot randomized controlled trial (RCT) aiming to test the feasibility of all components of an empowerment-based intervention using PROMs as dialogue support in clinical diabetes consultations, and to address the uncertainties associated with running a fully powered evaluation study.

Methods and analysis We will undertake a two arm pilot RCT of an intervention utilizing the Problem Areas In Diabetes scale (PAID) in clinical diabetes consultations in order to conclude whether a fully powered trial is appropriate and/or feasible. The study will also include qualitative in-depth interviews with participants and health care providers. Our objectives are to: 1) evaluate the recruitment procedures and attrition rates; 2) evaluate the performance of the randomization procedure; 3) evaluate the participants' mean scores on the outcome measures before and after the intervention; 4) evaluate if the intervention consultations are acceptable and feasible; and 5) explore patients' and health care providers experiences with the use of PAID as dialogue support and empowerment-based communication skills in clinical diabetes consultations. The quantitative data analysis includes descriptive statistics (frequencies, percentages, means, SD and CI). For the qualitative data, we will perform thematic analysis.

1
2
3 **Ethics and dissemination** Ethical approval has been obtained from the Western Norway
4
5 Regional Committee for Medical and Health Research Ethics (2017/1506/REC west). The
6
7 trial is registered in ClinicalTrials.gov (ID: NCT03471104).
8
9

10 **Keywords** Type 1 diabetes, Diabetes distress, Patient-Reported Outcome Measures
11
12 (PROMs), Complex intervention
13
14
15
16
17
18

19 **Strengths and limitations of the study**

20
21

- 22 • This is a study with the potential to provide new knowledge about the use of Patient-
23
24 Reported Outcome Measures (PROMs) as dialogue support in clinical diabetes
25
26 consultations among patients with type 1 diabetes.
27
28
- 29 • The use of the Medical Research Council's framework as a guide for the development of
30
31 study intervention initiatives like this is a strength because the feasibility and uncertainties
32
33 related to a fully-powered RCT can be illuminated before a resource intensive fully
34
35 powered RCT is conducted.
36
37
- 38 • A key challenge includes possible contamination of the control group although the
39
40 completed PROMs will not be available in the electronic patient records (EPR) of the
41
42 participants in the control group.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

The management of type 1 diabetes (T1D) is complex and people living with the condition need to make numerous daily choices related to their medical treatment.[1, 2] They need to monitor their blood glucose and administer insulin several times each day. The burden of living with T1D remains a challenge despite new insulin types and advances in insulin delivery and glucose monitoring technologies.[3] Many Norwegian adults with T1D do not achieve the recommended treatment goals for glycaemic control.[4, 5] This poor goal attainment might be due to inappropriate choice of insulin regimen for the individual, but research has also shown psychological and emotional aspects are important barriers to satisfactory diabetes self-management.[6]

The psychological and emotional impact of living with diabetes is often unrecognized and/or underreported in diabetes care.[7, 8] Diabetes distress, which reflects the emotional response to the burden, worries, anxieties, frustrations and stressors associated with managing diabetes in everyday life,[9, 10] is found to be associated with decreased glycaemic control.[11, 12] Therefore, regular assessment of diabetes distress is recommended.[13] Such assessment is considered feasible and beneficial to promote the recognition of psychological and emotional issues that affect diabetes self-management.[9, 14]

Collecting Patient-Reported Outcome Measures (PROMs) involves asking people to complete questionnaires concerning the impact of their condition and its treatment on their health.[15]

The integration of PROMs in clinical practice has the potential to improve care for people with diabetes and other chronic conditions by screening for and identifying problems, monitoring progress over time, improving patient-clinician communication and enabling people to become more involved in managing their own health.[16, 17] However, using

1
2
3 PROMs in itself may not affect health outcomes. The collection of PROMs should be
4
5 accompanied by a discussion of results to elaborate on any problems identified by the
6
7 assessment.[14, 17] Previous research has shown that the use of PROMs to monitor diabetes
8
9 psychological distress and general wellbeing followed by a discussion of outcomes improves
10
11 psychological wellbeing in both adults and youth with diabetes.[14, 18, 19] In the Cross-
12
13 National Diabetes Attitudes, Wishes, and Needs (DAWN) MIND study,[14] the skills used in
14
15 discussions of PROMs data regarding diabetes distress and wellbeing were based on
16
17 empowerment theory and patient-centred communication. Empowerment in nursing and
18
19 health care is defined as a motivational approach and process using specific counselling and
20
21 communication techniques to assist patients in making health-promoting behaviour
22
23 changes.[20] The approach is patient-centred with the health care providers facilitating and
24
25 providing information and knowledge to assist the patients in taking informed decisions. The
26
27 desired outcomes in the empowerment process are control and self-determination. A
28
29 systematic review by Chen & Li [21] states that interventions aiming to empower people with
30
31 chronic illnesses are able to improve health status, improve outcome indicators of
32
33 psychological and social aspects, and improve self-management. The authors of the DAWN
34
35 MIND study suggest further research on process evaluations to explore the role of
36
37 empowerment- and patient-centred skills such as active listening, use of open-ended
38
39 questions, and promoting active patient participation in the decision making process.[14]
40
41
42
43
44
45
46

47 The overarching aim of the Diabetes Patient-Reported Outcome Measures trial
48
49 (DiaPROM trial) is to develop, test and evaluate a structured empowerment-based
50
51 intervention using PROMs regarding diabetes distress as dialogue support in clinical diabetes
52
53 consultations among adults with T1D. Our proposition is that the DiaPROM intervention
54
55 initiative will reduce diabetes distress and further improve overall wellbeing, improve
56
57 perceived competence for diabetes management and improve glycaemic control. Based on
58
59
60

1
2
3 experiences and research,[14, 18, 19] we also believe that improved focus on the
4
5 psychological and emotional burden of the disease will improve satisfaction with diabetes
6
7 follow-up. This paper describes the protocol for a pilot randomized controlled trial (RCT) to
8
9 test the feasibility of and uncertainties associated with a fully powered evaluation study.
10
11
12

13 **The development of the DiaPROM trial**

14
15
16

17 The DiaPROM trial is part of the implementation of PROMs in the Norwegian
18
19 Diabetes Register for Adults (NDR-A). We wanted to design a study to test a method for
20
21 utilizing the PROMs data in clinical diabetes practice. The study is multidisciplinary and
22
23 consists of several interacting components and a number of behaviours required by those
24
25 receiving and delivering the intervention. Thus, we consider the study as a complex
26
27 intervention with a need to develop and test the various components gradually before
28
29 conducting a fully powered RCT. As guidance in this process, we used the Medical Research
30
31 Council's framework (MRC framework) for the evaluation of complex interventions.[22, 23]
32
33 The framework describes four important phases in the development, evaluation and
34
35 implementation of a new intervention initiative: (1) the development phase, (2) the feasibility
36
37 and piloting phase, (3) the evaluation phase and (4) the implementation phase (figure 1).
38
39
40
41
42
43

44 The development of the DiaPROM trial took place during 2016 and 2017. Initially,
45
46 the essential tasks were to determine which PROMs to include and how patients should
47
48 complete the PROMs.
49
50

51 *PROMs to include*

52
53
54

55 We reviewed the literature to identify published articles on the use of PROMs as
56
57 dialogue support in clinical diabetes practice. We wanted to identify the most common used
58
59 PROMs to measure diabetes distress. We recognized that studies have primarily used PROMs
60

1
2
3 to evaluate interventions' effects; relatively few publications have reported on the use of
4
5 PROMs in clinical diabetes care. We did identify, however, the DAWN MIND study that
6
7 tested the feasibility and impact of the computer-assisted "Monitoring of Individual Needs in
8
9 Diabetes" procedure aimed to improve recognition and management of the psychological
10
11 needs of patients with diabetes by implementing PROMs in routine diabetes care.[14, 24]
12
13 Regular assessment of psychological needs was implemented as part of the annual review in
14
15 diabetes clinics across eight countries. The assessment included among others diabetes
16
17 distress measured by the Problem Areas in Diabetes (PAID) scale. Accordingly, Schmitt *et*
18
19 *al.*[25] emphasize the necessity of a justified choice of measurement and recommend the use
20
21 of the PAID when the clinical purpose is to bear in mind a variety of emotional concerns
22
23 related to living with diabetes. Some other studies have reported PAID as an appropriate
24
25 instrument for use in clinical diabetes consultations, as well.[26-30] The scale may contribute
26
27 to improved communication by making the dialogue between health care providers and
28
29 patients more therapeutic and goal oriented.
30
31
32
33
34

35 36 37 *Patient and public involvement*

38
39
40 Involving health service users throughout all phases of a study is important to provide
41
42 insight into patients' perspectives and ensure that the research focuses on issues relevant for
43
44 the health service users and the public.[31, 32] Patient and public involvement (PPI) is also
45
46 useful in terms of shaping the research processes.[31] In this study, we used the GRIPP2 short
47
48 form as guidance for including and reporting PPI.[32] To include the voice of the health
49
50 service users throughout the study, two people with diabetes have been included in the
51
52 DiaPROM project group, both experienced with PPI and research. They will contribute to all
53
54 phases of the study. Furthermore, we have included additional people with diabetes to share
55
56
57
58
59
60

1
2
3 their views on the various phases of the study, recruited mainly from national and local
4
5 diabetes associations.
6
7

8
9 A crucial question when we considered which PROMs to include in the study, was
10
11 what adult people with T1D perceived as the most important and relevant aspects to
12
13 emphasize in diabetes follow-up. Thus, in parallel with the literature review, we consulted the
14
15 health service users. In addition to the health service users in the project group, we met the
16
17 leader of the Norwegian Diabetes Association and a group of four representatives from the
18
19 local diabetes association (two with T1D and two parents of children with T1D where one had
20
21 type 2 diabetes herself). First, we used open question to the health service users to determine
22
23 which topics they perceived as important and relevant to include in a set of PROMs. After an
24
25 open discussion, we asked them to review several generic instruments (e.g. World Health
26
27 Organization's 5-item wellbeing index (WHO-5), RAND-12 Health Status Inventory (RAND-
28
29 12), Patient Activation Measure (PAM)) and diabetes-specific instruments (e.g. PAID,
30
31 Diabetes Distress Scale (DDS), Perceived Competence for Diabetes Scale (PCDS)). The user
32
33 representatives considered the advantages and shortcomings of using the 20 statements in
34
35 PAID as dialogue support in the intervention. They found the instrument relevant and suitable
36
37 to be used in the intervention.
38
39
40
41
42
43

44 *The PAID*

45
46
47 Based on the literature review and in accordance with the input from the health service
48
49 users, we chose the PAID scale for use in the study intervention. The participants' PAID
50
51 scores will constitute the basis for the dialogue in the clinical consultations. The scale was
52
53 developed to gain insight into the breadth of emotional responses to living with diabetes, and
54
55 consists of 20 statements regarding diabetes distress (e.g. "feeling constantly concerned about
56
57 food and eating", "worrying about low blood sugar reactions").[33-35] The scores are on a 5-
58
59
60

1
2
3 point Likert scale from 0 (not a problem) to 4 (serious problem). An item score of 3
4
5 (somewhat serious problem) or 4 (serious problem) indicates moderate to serious diabetes
6
7 distress related to the specific item. Scale scores are transformed to a 0-100 scale, with higher
8
9 scores indicating greater distress, and a PAID total score >40 suggests serious diabetes-related
10
11 distress. To identify both moderate and serious distress, we defined scores of concern as
12
13 PAID total scores ≥ 30 or single item scores of 3 or 4. The scale has been translated into
14
15 several languages, including Norwegian.[36]
16
17
18
19

20 *Method for completing PROMs*

21
22
23 The literature describes various methods for administration of PROMs such as paper-
24
25 based self-administration at home or in the clinic, interviews by telephone or personal
26
27 meetings, computer-assisted self-administration in the clinic or mail- or web-based
28
29 administration from patients' homes.[16, 17] Electronic PROMs collection is preferred since
30
31 the patients' responses can be transferred to the electronic patient records without scanning
32
33 paper forms or punching data.[17] In our study, we decided on computer-assisted
34
35 administration on a touchscreen computer in the outpatient clinic. Using this method has
36
37 advantages, such as efficient and simultaneous data entry and minor privacy challenges.
38
39
40
41
42

43 *Feasibility study*

44
45
46 We conducted a feasibility study in 2017 to examine the technical and practical
47
48 feasibility of collecting PROMs on a touchscreen computer in the outpatient clinic, and
49
50 evaluate the participants' perceived understanding and relevance of the items in the PAID and
51
52 the included outcome measures. We also evaluated the acceptability of completing PROMs
53
54 annually. Field observations and comments from the participants provided data on the
55
56 technical and practical procedures. Sixty-nine individuals with T1D ≥ 40 years participated in
57
58
59
60

1
2
3 the study and 83% of them reported that, to a high or a very high degree, they would be
4
5 positive about an annual completion of PROMs. However, almost 20% of 137 invited patients
6
7 did not show up at the clinic (change of appointments, sick, no reason given), and most of the
8
9 invited ones did not go directly to the computer on arrival at the clinic as instructed in the
10
11 information sheet. Thus, we developed clearer information and procedures for the pilot study
12
13 to avoid loss of potential participants among those invited. Further analyses of the results
14
15 from the feasibility study are ongoing, and we plan to publish these in a separate article.
16
17
18
19

20 **Aim**

21
22
23
24 The purpose of the pilot RCT reported here is to test the feasibility of the proposed
25
26 DiaPROM trial components and address the uncertainties associated with running a fully
27
28 powered RCT, in order to conclude whether such a trial is appropriate and/or feasible. Our
29
30 objectives are to:
31
32
33

- 34 1. evaluate the recruitment procedures and attrition rates;
- 35 36 2. evaluate the performance of the randomization procedure;
- 37 38 3. evaluate the participants' mean scores on the outcome measures before and after the
39 40 intervention;
- 41 42 4. evaluate if the intervention consultations are acceptable and feasible; and
- 43 44 45 46 47 48 49 50 51 5. explore patients' and health care providers' experiences with the use of PAID as dialogue
52 support and empowerment-based communication skills in clinical diabetes
53 consultations.

54 **METHODS AND ANALYSIS**

55
56
57 We will undertake a two arm pilot RCT with embedded qualitative study on
58
59 participants' and health care providers' views of the DiaPROM intervention initiative. We
60

1
2
3 report our protocol here using the SPIRIT checklist ([http://www.spirit-statement.org/wp-](http://www.spirit-statement.org/wp-content/uploads/2013/01/SPIRIT-Checklist-download-8Jan13.pdf)
4 [content/uploads/2013/01/SPIRIT-Checklist-download-8Jan13.pdf](http://www.spirit-statement.org/wp-content/uploads/2013/01/SPIRIT-Checklist-download-8Jan13.pdf)).
5
6
7

8 **Participants and eligibility criteria**

9
10
11
12 As recommended for pilot RCTs,[37] we will include 80 participants: 40 in the
13 intervention group and 40 controls. Participants will have T1D for at least 1 year and be aged
14 ≥ 18 to < 40 years. We will exclude people who are unable to read or complete the PROMs on
15 the touchscreen computer. Furthermore, we will exclude pregnant woman, patients with
16 known and recorded cognitive deficiency (e.g. Down's syndrome, Alzheimer), severe somatic
17 comorbidity (e.g. end stage renal disease, severe heart failure, severe cancer), and/or a major
18 psychiatric diagnosis (e.g. severe depression or bipolar disorder, schizophrenia) as diabetes
19 distress is often neither ethical nor possible to discuss with these group of patients. Eligible
20 participants will receive information and consent forms by regular mail before their annual
21 diabetes consultation at the clinic. The information form will include information about the
22 possibility to withdraw from the study at any time point without consequences.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Randomization procedure and allocation concealment**

40
41
42 We will randomize eligible and consenting participants, using computer-generated
43 block randomization at the patient level, stratified for gender, immediately after the
44 participants have completed both the PAID and the self-reported outcome measures. When
45 participants complete the measures on the touchscreen computer in the outpatient clinic, they
46 will receive an individual four-character code. When the physician downloads the PROMs
47 data using the code, a concealed computerized allocation will take place. Information about
48 which group the person is allocated to will appear on the computer screen and the physician
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 will inform the participant immediately. It is not possible to blind either participants or health
4
5 care providers.
6
7

8 **Trial intervention**

9
10
11
12 After participants have completed the PAID scale, physicians download the scores
13
14 into the participants' electronic patient record (EPR) as part of the annual consultation (figure
15
16 2). Physicians then review and discuss the PAID scores briefly with participants. Participants
17
18 with one or more single PAID item(s) score of 3 or 4 (somewhat serious or serious problem),
19
20 or PAID total score ≥ 30 , will be referred to additional diabetes nurse consultations.
21
22 Participants with lower scores will receive regular follow-up according to usual clinical
23
24 protocols.
25
26
27

28
29 Additional nurse follow-up will consist of at least two consultations. The first will
30
31 take place within four weeks after randomization, and the second within a further three
32
33 months. After the second nurse consultation, the nurse and the participant will agree any
34
35 further follow-up until the next annual consultation with the physician. Diabetes nurses will
36
37 review PAID scores and discuss the reported problem areas and distress with participants by
38
39 following a communication manual based on key elements from empowerment theory and
40
41 self-determination theory, such as empathetic communication and autonomy support.[38-40]
42
43 These communication skills involve "active listening", "asking open questions",
44
45 "responding", "summing up" and "agreeing on goals and actions to take". Nurses will record
46
47 their work on participants' problem areas, goals and actions. The intervention will last for a
48
49 maximum of one year, until the next annual consultation.
50
51
52
53
54
55
56
57
58
59
60

Control procedure

The control group will receive “care as usual” which does not include a structured focus on psychological and emotional diabetes distress. For most patients the annual consultation normally constitute “care as usual”. Although all participants will complete the PAID before randomization, for control participants the scores will not be accessible to clinicians in the EPR until the study is completed. For ethical reasons, we will not prevent physicians discussing psychological or emotional issues with participants in the control group if participants specifically raise such an issue. Unlike participants in the intervention group, such discussions will not be structured with reference to PAID data. We will identify to what extent such discussions have taken place by reviewing participants’ EPR.

Training of health care providers

Before the study commences, we will have a one-hour meeting with the participating physicians, and they will be trained in how to download the PAID scores into the EPR and how to briefly discuss the scores in the annual consultations. Further, they will get both oral information and written instructions regarding the interpretation of the PAID scores including instructions on the criteria for referral of participants to extra follow-up by the diabetes nurses. Nurses will get both oral and written information and a 2 x 1 hour training in how to interpret scores and discuss the reported problem areas, how to follow the communication manual in the consultations, and how to agree upon goals and actions to take with the participants.

Data collection and outcome measures

All participants (both intervention and control groups) will complete the outcome measures electronically before the annual consultation at baseline and after 12 months. After

1
2
3 the annual consultation, the participants will complete a paper-based questionnaire about their
4 experience and satisfaction with the diabetes follow-up. We will evaluate the recruitment
5 procedures and attrition rates by observing and monitoring number of eligible participants
6 invited, number of invited people declining participation, number of people who attended the
7 clinic, number of intervention participants attended the nurse consultations, and number of
8 consultations conducted. We will also observe and document the technical performance of the
9 randomization procedure. Finally, we will document all types of contacts between participants
10 and the diabetes outpatient clinic for all participants throughout the study period.
11
12
13
14
15
16
17
18
19
20
21

22 To describe the study sample and evaluate the technical procedure of data retrieval
23 from EPR, we will perform a computerized retrieval of the following variables from the
24 participants' EPR: sex, age, ethnicity, body mass index, diabetes duration, HbA_{1c} (secondary
25 outcome), insulin regimen, insulin doses, severe hypoglycaemic episodes needing assistance
26 in the past year, hospitalizations, co-morbidities and diabetes late complications.
27
28
29
30
31
32
33
34

35 The outcome measures to evaluate the effect of the intervention in the evaluation
36 phase of the study (phase 3), were chosen based on a literature review and considerations
37 among the researchers and the health service users. We decided upon the DDS as primary
38 outcome. DDS measures diabetes distress and contains 17 items and 4 subscales: emotional
39 burden (5 items), physician-related distress (4 items), regimen distress (5 items) and diabetes-
40 related interpersonal distress (3 items).[41] The scores are on a 6-point Likert scale from 1
41 (not a problem) to 6 (serious problem) with mean total or subscale score from 1 to 6.[42]
42 Total or subscale scores >3 are defined as high levels of distress. The DDS has previously
43 shown satisfactory psychometric properties to map diabetes distress, and might have
44 advantages for use as outcome measure in clinical trials because it contributes to identify sub-
45 domains of distress.[11, 25, 36] To measure the secondary outcomes, overall wellbeing and
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 perceived diabetes competence, we have included the WHO-5[43-45] and the PCDS.[46-48]
4
5 We will use HbA1c as the target for glycaemic control.
6
7

8
9 We will invite all participants from the intervention group and all health care
10 providers (physicians and diabetes nurses) participating in the intervention group to individual
11 in-depth interviews to collect qualitative data on their experiences with the intervention,
12 including the use of PAID as dialogue support in clinical consultations. This will provide a
13 sample of about 15-20 participants and 10-15 health care providers. All interviews will be
14 conducted at the outpatient clinic, and will be audio recorded after obtaining consent from
15 participants.
16
17
18
19
20
21
22
23
24
25

26 **Data analysis**

27
28
29 We will use Stata SE 15 for Windows for all statistical analyses,[49] and for data entry
30 range checks for data values will be performed. We will report the recruitment of participants
31 and the number of trial dropouts descriptively (frequencies and percentages). Further, we will
32 report the means, SD and CI of the DDS and the other outcome measurements before and
33 after the intervention period for both the intervention and control groups. As the study is a
34 pilot and the sample size is small, we will not perform inferential statistics and analyze
35 between group calculations. The participants' PAID scores will be analyzed descriptively
36 (mean, SD), as well.
37
38
39
40
41
42
43
44
45
46
47
48

49 We will transcribe verbatim and analyse participants' and health care providers'
50 experiences with the intervention, by using thematic analysis.[50] Thematic analysis is a
51 flexible qualitative method without any specific theoretical foundation and consists of six
52 steps: 1) transcribing, reading and re-reading, 2) generating initial codes, 3) searching for
53 themes, 4) reviewing themes, 5) defining and naming the themes, and 6) producing the report.
54
55
56
57
58
59
60

ETHICS AND DISSEMINATION

The Norwegian Regional Committee for Medical and Health Research Ethics has approved the study (2017/1506/REK west). Haukeland University Hospital, Bergen, Norway is the responsible research institution (trial sponsor) where the study data will be stored on a secure research server. In order to protect confidentiality, names of the potential and enrolled participants will be stored separate from the other study data. Only the principle investigator and other clearly identified members of the project group have access to the study data. If important protocol modifications happen, this will be communicated to the ethic committee and ClinicalTrials.gov. Further information can be obtained from ClinicalTrials.gov, registration number NCT03471104.

Completing the PROMs may activate latent psychological or psychosocial problems and negative feelings. To care for any participants in the control group reporting worryingly high levels of distress (e.g. above cut points for severe levels of distress measured by PAID and/or DDS), the research team will continuously review the reported distress levels. We will discuss potential needs for more intensive care or referral to psychological or psychiatric follow-up for those reporting worryingly levels of distress with the physicians and diabetes nurses.

We will present the findings of the study phases at national and international conferences and submit manuscripts to peer-reviewed journals and popular science journals. Further, we will also publish the findings in popular science journals, public newspapers and journals for relevant user groups. One of the health service users will participate in the writing and publication process.

DISCUSSION

In the pilot RCT study described in this protocol, we aim to test the feasibility of, and address the clinical and methodological uncertainties associated with running a fully powered RCT testing the effect of an intervention incorporating the use of PAID to decrease diabetes distress among people with T1D. The study will provide knowledge on the use of PAID in clinical diabetes practice, although the purpose primarily is to prepare the ground for the design and conduct of a full powered RCT. In addition, the qualitative evaluation will provide important knowledge on the specific empowerment-based communication skills used to discuss PAID scores of concern in the clinical consultations. In an upcoming fully powered evaluation study (phase 3) we plan to test the effect of the entire intervention package including both the use of PAID and the empowerment-based follow-up. A major limitation of such an effect study is the lack of information on how specific parts of the intervention may affect the results.

Diabetes distress has been shown to be a barrier for satisfactory glycaemic control, [11, 12] and a more structured focus on diabetes distress, may have the potential to improve long-term health for people with T1D by reducing the distress and improving glycaemic control. A previous literature review by Carlsen *et al.* [51] found that the use of PAID could benefit patients but emphasized the need for follow-up studies to evaluate whether the PAID should be implemented in routine diabetes care to enhance a more structured focus on diabetes distress.

The choice of utilizing PAID as dialogue support in the intervention and the DDS as the primary outcome measure is in accordance with previous research. Both instruments have previously shown satisfactory psychometric properties to map individual levels of diabetes

1
2
3 distress, but it has been claimed that the PAID has advantages for use in clinical practice and
4 that the DDS have advantages for use in clinical trials, because it also contributes to
5 identifying sub-domains of distress.[11, 25, 36] However, there will be an overlap between
6 the intervention measure (PAID) and the primary outcome measure (DDS) in this study.
7
8 Using PAID in the intervention may prime the participants' responses to the DDS, but the
9 inclusion of WHO-5 and the PCDS as additional outcomes may compensate for the overlap
10 between PAID and DDS. Previous research has shown links between diabetes distress
11 measured by PAID, and wellbeing and perceived competence. Snoek *et al.*[14] indicated an
12 overlap between predictors for diabetes distress and general wellbeing measured by WHO-5,
13 and Mohn *et al.*[48] showed an association between greater diabetes distress and lower
14 perceived competence for diabetes self-management measured by PCDS.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Strengths and limitations**

31
32 The use of the MRC framework is a strength in the development of this study, because
33 it includes several complex and interacting components that need to be considered and tested
34 with the purpose to reveal uncertainties before conducting a fully powered RCT. In addition,
35 the use of the GRIPP2 short form to guide the PPI throughout all phases of the development
36 of the intervention initiative is considered a strength. The health service users included in the
37 project have influenced among others the choice of PROMs, the choice of the theoretical
38 foundation for the intervention, and the discussions related to the qualitative component of the
39 study.
40
41
42
43
44
45
46
47
48
49

50
51 We have included primarily disease-specific outcome measures, but also one generic
52 PROM (WHO-5). Disease-specific PROMs are used to capture information that is most
53 pertinent to particular patient groups, but they might miss domains affecting the patient that
54 are unrelated to their disease.[16, 52] Generic instruments may capture broad dimensions of
55
56
57
58
59
60

1
2
3 health and allow for comparisons between populations but might not be sensitive to changes
4
5 in disease-specific health domains over time or in relation to interventions.[15]
6
7

8
9 The fact that the control group in the study will also complete the PAID and the
10
11 evaluation PROMs before the annual diabetes consultation, and that the same physicians meet
12
13 participants from both the intervention and the control groups might lead to intervention
14
15 contamination challenges. This might be a challenge although the scores will not be
16
17 accessible in the electronic patient records of participants in the control group.
18
19

20 21 **Acknowledgements** 22 23

24
25
26 Thanks to the Norwegian Nurses Association, the Norwegian Diabetes Association
27
28 and Western Norway University of Applied Sciences for funding the study. Thanks also to the
29
30 Norwegian Diabetes Register for Adults and DIPS AS for fruitful collaboration. Further, we
31
32 thank all the health care providers and the health care service user representatives involved in
33
34 the study. Thanks also to senior research fellow Peter Craig for giving us the permission to
35
36 reproduce the figure describing the study phases in the development of a complex
37
38 intervention.
39
40
41

42 43 **Contributors** 44 45

46
47 AH and MG applied for funding of the trial. AH, IH, MG and RBS designed the study
48
49 with involvement of GST, DR and RMN. AH wrote the first draft of the study protocol. All
50
51 other authors have edited and critically reviewed the manuscript, and all authors read and
52
53 approved the final version.
54
55
56
57
58
59
60

Funding

The study is funded by the Norwegian Nurse Association, Western Norway University of Applied Sciences, the Norwegian Diabetes Association and the Norwegian Diabetes Register for Adults. The first two funded a postdoctoral position and a PhD position, respectively. The last two contributed with running funds.

Competing interests

None declared.

Patient consent

There is no patient data included in this report.

REFERENCES

1. American Association of Diabetes Educators (AADE). AADE7 Self-Care Behaviors. *Diabetes Educ* 2008;34:445-9.
2. American Diabetes Association (ADA). Introduction: standards of medical care in diabetes. *Diabetes Care* 2018;41(Suppl 1):1-2. Available from: <https://doi.org/10.2337/dc18-Sint01> (Accessed Jan 22, 2018).
3. Jones A, Vallis M, Pouwer F. If it does not significantly change HbA 1c levels why should we waste time on it? A plea for the prioritization of psychological well-being in people with diabetes. *Diabet Med* 2015;32:155-63.

- 1
2
3 4. Cooper JG, Claudi T, Thordarson HB, *et al.* Treatment of type 1 diabetes in the
4
5 specialist health service-data from the Norwegian Diabetes Register for Adults. *J*
6
7 *Norwegian Med Assoc* 2013;133:2257.
8
9
- 10 5. Carlsen S, Skrivarhaug T, Thue G, Cooper JG, Goransson L, Lovaas K, *et al.*
11
12 Glycemic control and complications in patients with type 1 diabetes - a registry-based
13
14 longitudinal study of adolescents and young adults. *Pediatr Diabetes* 2017;18:188-95.
15
16
- 17 6. Pouwer F, Nefs G, Nouwen A. Adverse effects of depression on glycemic control and
18
19 health outcomes in people with diabetes: a review. *Endocrinol Metab Clin North Am*
20
21 2013;42:529-44.
22
23
- 24 7. Pouwer F, Beekman ATF, Lubach C, *et al.* Nurses' recognition and registration of
25
26 depression, anxiety and diabetes-specific emotional problems in outpatients with
27
28 diabetes mellitus. *Patient Educ Couns* 2006;60:235-40.
29
30
- 31 8. Peyrot M, Rubin RR, Lauritzen T, *et al.* Psychosocial problems and barriers to
32
33 improved diabetes management: results of the Cross-National Diabetes Attitudes,
34
35 Wishes and Needs (DAWN) Study. *Diabet Med* 2005;22:1379-85.
36
37
- 38 9. Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in
39
40 patients with diabetes: a call for greater clarity and precision. *Diabet Med*
41
42 2014;31:764-72.
43
44
- 45 10. Snoek FJ, Bremmer MA, Hermanns N. Constructs of depression and distress in
46
47 diabetes: time for an appraisal. *Lancet Diabetes Endocrinol* 2015;3:450-60.
48
49
- 50 11. Strandberg RB, Graue M, Wentzel-Larsen T, *et al.* Longitudinal relationship between
51
52 diabetes-specific emotional distress and follow-up HbA_{1c} in adults with Type 1
53
54 diabetes mellitus. *Diabet Med* 2015;32:1304-10.
55
56
57
58
59
60

12. Fisher L, Hessler D, Polonsky W, *et al.* Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time. *J Diabetes Complications* 2016;30:1123-8.
13. International Diabetes Federation. *International Diabetes Federation Diabetes Atlas* [Online]. 8th ed. International Diabetes Federation; 2017. Available from: <http://www.diabetesatlas.org/resources/2017-atlas.html> (accessed Jan 15, 2018).
14. Snoek FJ, Kersch NY, Eldrup E, *et al.* Monitoring of Individual Needs in Diabetes (MIND)-2: follow-up data from the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) MIND study. *Diabetes Care* 2012;35:2128-32.
15. Greenhalgh J, Dalkin S, Gooding K, *et al.* Functionality and feedback: a realist synthesis of the collation, interpretation and utilisation of patient-reported outcome measures data to improve patient care. *Health Serv Deliv Res* 2017;5.2.
16. Snyder CF, Aaronson NK, Choucair AK, *et al.* Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. *Qual Life Res* 2012;21:1305-14.
17. Eton DT, Beebe TJ, Hagen PT, Halyard MY, Montori VM, Naessens JM, Sloan JA, Thompson CA, Wood DL. Harmonizing and consolidating the measurement of patient-reported information at health care institutions: a position statement of the Mayo Clinic. *Patient Related Outcome Measures*. 2014;5:7-15. doi: 10.2147/PROM.S55069.
18. Pouwer F, Snoek FJ, van der Ploeg HM, Adèr HJ, Heine RJ, Monitoring of psychological well-being in outpatients with diabetes: effects on mood, HbA(1c), and the patient's evaluation of the quality of diabetes care: a randomized controlled trial. *Diabetes Care* 2001;24:1929-1935.

19. de Wit M, Delemarre-van de Waal HA, Bokma JA, *et al.* Monitoring and discussing health-related quality of life in adolescents with type 1 diabetes improve psychosocial well-being: a randomized controlled trial. *Diabetes Care* 2008;31:1521-1526.
20. Ellis-Stoll CC, Popkess-Vawter S. A concept analysis on the process of empowerment. *Advances in Nursing Science* 1998;21(2):62-68.
21. Chen YC, Li IC. Effectiveness of interventions using empowerment concept for patients with chronic disease: a systematic review. *JBI library of systematic reviews* 2009;7 (27):1179.
22. Craig P, Dieppe P, Macintyre S, *et al.* Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;337:979-83.
23. Craig, P. Developing and evaluating complex interventions: reflections on the 2008 MRC guidance. *Int J Nurs Stud* 2013;50:585-92.
24. Snoek, FJ, Kersch NY, Eldrup E, *et al.* Monitoring of Individual Needs in Diabetes (MIND): baseline data from the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) MIND study. *Diabetes Care* 2011;34:601-3.
25. Schmitt A, Reimer A, Kulzer B, *et al.* How to assess diabetes distress: comparison of the Problem Areas in Diabetes Scale (PAID) and the Diabetes Distress Scale (DDS). *Diabet Med* 2016;33:835-43.
26. Chawla A, Saha C, Marrero DG. A novel application of the problem areas in diabetes (PAID) instrument to improve glycemic control and patient satisfaction. *Diabetes Educ* 2010;36:337-44.

- 1
2
3 27. van Bastelaar KMP, Pouwer F, Geelhoed-Duijvestijn PHLM, *et al.* Diabetes-specific
4 emotional distress mediates the association between depressive symptoms and
5 glycemic control in type 1 and type 2 diabetes. *Diabet Med* 2010;27:798-803.
6
7
- 8
9
10 28. Meeuwissen JAC, Hollemann GJM, de Jong FJ, *et al.* Screening and guided self-help
11 intervention for anxiety and depression in patients with type 2 diabetes. A new role for
12 diabetes nurses in primary care? *Eur Diabetes Nurs* 2011;8:47-52.
13
14
- 15 29. Fler J, Tovote KA, Keers JC, *et al.* Screening for depression and diabetes-related
16 distress in a diabetes outpatient clinic. *Diabet Med* 2013;30:88-94.
17
18
- 19 30. Reddy J, Wilhelm K, Campell L. Putting PAID to diabetes-related distress: the
20 potential utility of the problem areas in diabetes (PAID) scale in patients with diabetes.
21 *Psychosomatics* 2013;54:44-51.
22
23
- 24 31. Staley K. 'Is it worth doing?' Measuring the impact of patient and public involvement
25 in research. *Res Involv Engagem* 2015; 1:6.
26
27
- 28 32. Staniszewska S, Brett J, Simera I, *et al.* GRIPP2 reporting checklists: tools to improve
29 patient and public involvement in research. *BMJ* 2017;358:j3453.
30
31
- 32 33. Polonsky WH, Anderson BJ, Lohrer PA, *et al.* Assessment of diabetes-related distress.
33 *Diabetes Care* 1995;18:754-60.
34
35
- 36 34. Welch GW, Jacobson AM, Polonsky WH. The Problem Areas in Diabetes scale: an
37 evaluation of its clinical utility. *Diabetes Care* 1997;20:760-6.
38
39
- 40 35. Welch G, Weinger K, Anderson B, *et al.* Responsiveness of the Problem Areas in
41 Diabetes (PAID) questionnaire. *Diabet Med* 2003;20:69-72.
42
43
- 44 36. Graue M, Haugstvedt A, Wentzel-Larsen T, *et al.* Diabetes-related emotional distress
45 in adults: reliability and validity of the Norwegian versions of the Problem Areas in
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 Diabetes Scale (PAID) and the Diabetes Distress Scale (DDS). *Int J Nurs Stud*
4
5 2011;49:174-182.
6
7
8 37. Richards DA, Hallberg IR. Section 2. Investigating feasibility and undertaking pilot
9 testing of complex interventions. *Complex Interventions in Health. An Overview of*
10
11 *Research Methods*. Routledge; 2015:121-82.
12
13
14
15 38. Anderson RM, Funnell M. *The Art of Empowerment: Stories and Strategies for*
16
17 *Diabetes Educators*. Alexandria, Virginia: American Diabetes Association; 2000.
18
19
20
21 39. Deci EL, Ryan RM. *Handbook of Self-determination Research*. Rochester, NY:
22
23 University of Rochester Press; 2002.
24
25
26 40. Zoffmann V, Hörnsten Å, Storbækken S, *et al*. Translating person-centered care into
27
28 practice: a comparative analysis of motivational interviewing, illness-integration
29 support, and guided self-determination. *Patient Educ Couns* 2016;99:400-7.
30
31
32
33 41. Polonsky WH, Fisher L, Psyd JE, *et al*. Assessing psychosocial distress in diabetes –
34
35 development of the Diabetes Distress Scale. *Diabetes Care* 2005;28:626-31.
36
37
38 42. Fisher L, Hessler D, Glasgow RE, *et al*. REDEEM: a pragmatic trial to reduce diabetes
39
40 distress. *Diabetes Care* 2013;36:2551-8.
41
42
43 43. de Wit M, Pouwer F, Gemke RBJ, *et al*. Validation of the WHO-5 Well-Being Index
44
45 in adolescents with type 1 diabetes. *Diabetes Care* 2007;30:2003-6.
46
47
48 44. Hajos TR, Pouwer F, Skovlund SE, *et al*. Psychometric and screening properties of the
49
50 WHO-5 well-being index in adult outpatients with Type 1 or Type 2 diabetes mellitus.
51
52 *Diabet Med* 2013;30:e63-9.
53
54
55 45. Topp CW, Østergaard SD, Søndergaard S, *et al*. The WHO-5 Well-Being Index: a
56
57 systematic review of the literature. *Psychother Psychosom* 2015;84:167-76.
58
59
60

- 1
2
3 46. Williams GC, McGregor HA, Zeldman A, et al. Testing a self-determination theory
4 process model for promoting glycemic control through diabetes self-management.
5
6
7
8 *Health Psychol* 2004;23:58-66.
9
- 10 47. Williams GC, McGregor HA, King D, et al. Variation in perceived competence,
11 glycemic control, and patient satisfaction: relationship to autonomy support from
12 physicians. *Patient Educ Couns* 2005;57:39-45.
13
14
15
16
17 48. Mohn J, Graue M, Assmus J, et al. Self-reported diabetes self-management
18 competence and support from healthcare providers in achieving autonomy are
19 negatively associated with diabetes distress in adults with type 1 diabetes. *Diabet Med*
20 2015;32:1513-19.
21
22
23
24
25
26
27 49. StataCorp LLC. STATA Data Analysis and Statistical Software. Stata SE 15 ed.
28 College Station, Texas, USA: StataCorp LLC; 2018.
29
30
31
32 50. Braun V, Clark V. Using thematic analysis in psychology. *Qual Res Psychol*
33 2008;3:77-101.
34
35
36
37 51. Carlsen K, Haugstvedt A, Graue M. [PAID as screening and working tool in clinical
38 consultations]. *Norwegian J Clin Nurs* 2015;10:228-37 [in Norwegian].
39
40
41
42 52. Black N, Burke L, Forrest CB, et al. Patient-reported outcomes: pathways to better
43 health, better services, and better societies. *Qual Life Res* 2016;25:1103-12.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1.** Key elements in the Medical Research Council’s guidance for developing,
4
5 evaluating and implementing complex interventions (MRC framework). Reproduced
6
7 from Craig *et al.*[17] with permission.
8
9

10
11 **Figure 2.** The study intervention in the DiaPROM trial.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1

Figure 1

92x49mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2 The intervention

Figure 2

338x190mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents

Section/item	Item No	Description	Answer (DiaPROM trial)
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	The title identify design, population, the intervention (use of PROMs) and trial acronym.
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Trial registration number is included (p. 2 and 15).
	2b	All items from the World Health Organization Trial Registration Data Set	All items have been checked and relevant items are included in the protocol.
Protocol version	3	Date and version identifier	Version 25.10.2018
Funding	4	Sources and types of financial, material, and other support	Funding statement is included in the paper (p. 18).
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	Included
	5b	Name and contact information for the trial sponsor	Name of trial sponsor is included (p.18).
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	Included (page 15 and 18).
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	Described in the introduction section (p. 4-5) and aim section (p. 9-10) .

	6b	Explanation for choice of comparators	Described (p. 11-12)
Objectives	7	Specific objectives or hypotheses	An overarching aim of the DiaPROM trial are described (p. 5), and the aim of the present pilot RCT are described in the aim section (p. 9-10)
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	Described in the methods section (starts on p. 10)
Methods: Participants, interventions, and outcomes			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Study setting and participants for the pilot study are described in the methods section (starts on p. 10).
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Described in the methods section (starts on p. 10).
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	Described in the methods section (starts on p. 10).
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	Described in the methods section (p. 13) and in the ethic section (p. 15-16).
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	N/A
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	Described in the methods section (p. 10-13)

Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	Primary and secondary outcomes for the forthcoming fully powered RCT are described (p. 5). The objectives for the present pilot RCT are described (p. 9-10), and the analyses of data (p. 14-15), time point for collecting outcome measures (p. 13-14), and explanations for clinical relevance of the DiaPROM trial (p. 4-5 and 16), as well.
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Described in the methods section (starts on p. 10). A figure describing the steps of the intervention is also included.
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	The rationale for number of participants is described in the methods section (p. 10).
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	Not relevant for a pilot study
Methods: Assignment of interventions (for controlled trials)			
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Included in the methods section (p. 11).
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	Described in the methods section (p. 11)
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Described in the methods section (p. 11)
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Described in the methods section (p. 11).

	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	The study is not blinded for the participants and the health care providers as stated (p. 11).
Methods: Data collection, management, and analysis			
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Plans for assessment and included measures are described in the methods section (p. 13-14). References to the included instruments are given.
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	The relevant information for a pilot RCT is described in the methods section (p. 13-14)
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	Data storage is described (p. 15). Data entry is described (p. 14). Reference to where details of data management procedures can be found is described (p. 12 and 15)
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	Statistical analysis plans for both quantitative and qualitative data are included (p. 14-15)
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	N/A for a pilot study.
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	N/A for a pilot study.
Methods: Monitoring			

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	None planned.
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	None planned.
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	Included in the ethics and dissemination section (p. 15-16).
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	Not planned.
Ethics and dissemination			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	Included (p.2 and 16)
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	Described in the ethics and dissemination section (p. 15-16).
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	Described in the method section (starts on p. 10)
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	Described in the ethics and dissemination section (p. 15-16).

1 2 3 4	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	Included (p. 18)
5 6 7	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	Described in the ethics and dissemination section (p. 15-16).
8 9 10	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
11 12 13 14 15 16	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	Described in the ethics and dissemination section (p. 15-16).
17 18 19		31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
20 21 22		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A
23 24	Appendices			
25 26 27	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Not available in English.
28 29 30 31 32	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A

33 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the
 34 protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)"
 35 license.
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46